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activity results from decreased PI3K/Akt/mTOR signaling at early time points and Rheb mislocalization at
later disease stages. As a result of mTORC1 dysregulation, HD mice have increased mortality, inability to
hypertrophy, and increased pathologic changes in response to stress. Notably, this phenotype is reversed in
HD mice with exogenously activated mTORC1. Thus, I propose that mHTT expression in HD hearts
dysregulates mTORC1 and leads to increased mortality with heart disease.
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ABSTRACT

CARDIAC EFFECTS OF HUNTINGTON’S DISEASE IN MURINE MODELS
Daniel D. Child
Beverly L. Davidson
Huntington’s disease (HD) is an autosomal dominant disease known for its severe
neurologic phenotype. However, the causative protein in HD, mutant huntingtin (mHTT), is widely
expressed across tissue types and may have profound consequences for peripheral organs.
Notably, heart disease is the second leading cause of death in HD patients, but if or how cardiac
mHTT expression causes pathology is still unknown. Here, I characterize the cardiac phenotype
in two HD mouse models and show that dysregulated mTORC1 activity is a key underlying
mechanism. I show that normal heart growth is limited in HD mouse models, with mass regulated
independent of systemic changes. Additionally, cardiac mTORC1 activity is decreased in HD
mice starting at a presymptomatic time point in a manner that requires cardiac mHTT expression.
The impaired activity results from decreased PI3K/Akt/mTOR signaling at early time points and
Rheb mislocalization at later disease stages. As a result of mTORC1 dysregulation, HD mice
have increased mortality, inability to hypertrophy, and increased pathologic changes in response
to stress. Notably, this phenotype is reversed in HD mice with exogenously activated mTORC1.
Thus, I propose that mHTT expression in HD hearts dysregulates mTORC1 and leads to
increased mortality with heart disease.
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CHAPTER I: INTRODUCTION
Huntington Disease
Huntington disease (HD) is a fatal, autosomal dominant neurodegenerative disease
characterized by a classic triad of uncontrolled movements (chorea), behavioral abnormalities,
and cognitive decline (1). HD has been recognized as a disorder since at least the middle ages,
but it was first described thoroughly in the scientific literature in 1872 by the eponymous George
Huntington, who, significantly, identified its heritable nature (2). The hunt for HD’s genetic etiology
began in earnest about a century after Huntington’s report, and in 1983, thanks to the cooperation
of large, affected families in the Lake Maracaibo region of Venezuela, the HD gene locus was
mapped to chromosome 4p16 (3). Ten years later, IT15 (interesting transcript 15) was identified
as the HD causal gene (4), the first disease-causing gene discovered through genetic linkage
analysis (5). IT15 has since been given the more descriptive name huntingtin (HTT).
HTT spans 10,366 base pairs with 67 exons, encodes the 348 kD protein Huntingtin
(HTT) (4), and is expressed widely across tissues and organ systems (6-9). HTT”s normal
function is not well understood, but it has an essential role in development evidenced by
embryonic lethality in HTT nulliparous mice at day E8.5 (10, 11). Interestingly, mice with neuronspecific HTT deletion are viable and have normal life span (12), underscoring HTT’s importance
in early non-CNS tissue. Mechanistically, HTT is predicted to play a scaffolding role in
intracellular signaling: HTT has been shown to interact with hundreds of different proteins in vivo
(13), and it is predicted to form an elongated superhelical solenoid structure due to a large
number of HEAT repeats (14). However, elucidating HTT’s specific mechanisms of action has not
been a primary focus within the research community because the mutation that causes HD
imparts gain-of-function toxicity and does not impair HTT’s normal function (15).
HD is caused by a CAG trinucleotide repeat expansion in HTT exon 1, which produces a
form of HTT that contains an elongated N-terminal polyglutamine tract (termed mutant HTT, or
mHTT) (4). mHTT forms intracellular aggregates and disrupts numerous cellular functions,
including, but not limited to, transcription regulation (16, 17), intracellular transport (18, 19),
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protein degradation (20, 21), cholesterol homeostasis (22, 23), and mitochondria biogenesis (24,
25). The mechanistic pathway leading from mHTT expression to cell death is still poorly
understood, but eventually mHTT expression causes profound neuronal death in the striatum and
other brain regions (26), leading to the classic HD presentation. CAG tract length determines
disease: individuals with less than 36 repeats in both HTT alleles are unaffected, those with 36-39
repeats in at least one allele are at risk (reduced penetrance), and individuals with 40 or higher
CAG repeats in at least one allele are considered affected (27). Additionally, age at onset
inversely correlates with CAG tract length (28, 29), and the phenomenon of anticipation—
developing disease symptoms at an age earlier than the previous generation—exists within HD
families due to progressive expansion of the mutant allele, particularly in the paternal alleles (27).
Very long CAG triplet repeat tracts can cause HD to manifest in childhood or adolescence and is
referred to as juvenile HD (30). Regardless of age at onset, death occurs on average 10-15 years
after symptoms appear (31).
There is currently no cure for HD, but antisense oligonucleotide (ASO) and adenoassociated virus (AAV)-mediated gene therapies to reduce HTT levels in the central nervous
system (CNS) have demonstrated safety and efficacy in animal models and are moving into or
progressing through clinical trials (32-35). This approach is very promising for treatment of the
neurologic symptoms, but HD also affects peripheral tissues with high metabolic demand (36-39).
Thus, CNS-specific therapies may unmask peripheral HD phenotypes and present new clinical
challenges.
HD Heart Phenotypes
An association between HD and the heart has been considered since the late 1980’s.
Heart disease is one of the leading causes of death in HD patients in both Danish and United
States populations, second only to pneumonia (40-42). Though these oft-cited statistics are
interesting, they were compiled from death certificate analyses and their accuracy thus depends
on the subjective judgement of the people completing the records. They are also unavoidably
vague about what is meant by “heart disease,” which can take on a myriad of forms. Fortunately,

2

later inquiries into large cardiac disease databases implicated heart failure in 30% of HD patients
compared to 2% of unaffected age- and sex-matched controls (43-45), providing strong evidence
in support of the association between HD and heart disease, but still failing to provide insight
regarding a specific phenotype. One of the rare studies to examine post-mortem HD hearts found
decreased heart size at autopsy (46), potentially ruling out an HD-associated hypertrophic or
dilated cardiomyopathy, but the specific heart phenotype occurring in HD is still poorly
understood.
Limited studies have concluded that neuronal heart regulation is affected in HD, possibly
leading to heart disease. In a survey of systemic HD signs and symptoms, both pre-manifest and
symptomatic HD patients reported increased frequency of autonomic abnormalities including
gastrointestinal, genitourinary, and cardiovascular problems such as lightheadedness on standing
relative to age- and sex-matched controls (47). Accordingly, the few clinical studies that have
examined the heart in HD patients largely focused on autonomic nervous system (ANS)
regulation and employed noninvasive, autonomic function analysis tools—sympathetic skin
response, heart rate variability (HRV) measures, and blood pressure changes. Early studies
found that the balance between parasympathetic and sympathetic branches of the ANS is
affected in HD patients and worsens with disease progression, and suggested that sympathetic
activity was favored in HD patients (48, 49). A more sensitive analysis of HRV and blood pressure
changes under various challenges in pre-manifest and early-stage HD patients concluded that
increased sympathetic tone was secondary to parasympathetic dysfunction (50). These
conclusions were supported by a later study that observed decreases in HRV measurements on
head-up tilt that specifically represent impaired cardiovagal regulation (51).
One of the hypotheses stemming from these findings is that the dysautonomia leading to
augmented sympathetic activity in HD patients may predispose to fatal arrhythmias, thereby
explaining the heart disease-related mortality (48, 51). Indeed, decreased parasympathetic tone
is considered to be pro-arrhythmic (52) and predisposes to sudden cardiac death even in healthy
subjects (53, 54). However, history of arrhythmia—or any other form of heart disease—is one of
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the exclusion criteria for many HD-related clinical studies (44), thus introducing a selection bias
into many reports. At the time of writing this dissertation, only one study has been reported
specifically looking for conduction abnormalities in HD patients: electrocardiograms in 538 earlystage HD patients found increased rates of bradycardia and prolonged intraventricular
conduction, which could lower the threshold for arrhythmias and accelerate other heart
pathologies (55). These findings are especially interesting given the data supporting impaired
parasympathetic activity—which usually causes tachycardia—and suggest that both heartspecific and neuronal abnormalities occur in HD patients. While these studies show altered ANS
regulation of the heart in HD, they tend to be limited by small sample sizes and the accuracy of
HRV measurements (56). Thus, while HD patients may indeed experience ANS abnormalities,
the functional consequences remain unknown.
There have been no studies to date examining functional or molecular cardiac
parameters in HD. This gap in knowledge exists partially because of limited resources: heart and
other peripheral tissues are not routinely collected for banking, and parameters related to
cardiovascular health are not included in any of the large HD patient observational studies and
databases, including PREDICT-HD, TRACK-HD, REGISTRY, and Enroll-HD (57-59). Considering
heart disease is common in the general population, fully characterizing the HD heart phenotype
will likely require a relatively large sample size drawn from multiple patient populations.
HD Animal Models
While the HD cardiac phenotype has not been well-characterized in humans, the heart in
HD animal models have been more thoroughly investigated. One of the primary challenges in
modelling HD in flies or mice is timing: the average CAG repeat number in HD patients (~42)
does not manifest disease for several decades, and therefore repeat lengths of this size do not
affect shorter-lived species. Inducing a phenotype in animal models requires the CAG repeat
number to be significantly increased and/or the toxic product to be expressed at high levels.
Thus, genetic animal models for HD fall into one of three categories: transgenic fragment,
transgenic full-length, and knock-in models.
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Transgenic fragment models
Transgenic fragment models are designed based on the observation that neuronal
inclusion bodies in post-mortem HD brain samples contain high amounts of N-terminal mHTT
cleavage products, suggesting that a mHTT fragment containing the expanded polyglutamine
(polyQ) tract is sufficient to induce toxicity (60, 61). Indeed, mHTT N-terminal fragments are more
cytotoxic than full-length mHTT in experimental systems (62), and transgenic mHTT fragment
models recapitulate HD-like neurologic and metabolic phenotypes (63-66). Given the relative
ease of working with a smaller fragment compared to full-length HTT, numerous transgenic
models have been made for HD research. The expressed fragment in these models can range in
size from a long polyQ peptide (67, 68) to several N-terminal mHTT exons (64). The most
commonly used HD transgenic fragment model is the R6/2 mouse, which generally express HTT
exon 1 with 141-157 CAG repeats from the human HTT promoter. However, the mouse threshold
for CAG tract instability seems to be around 100 repeats (69-71), so the R6/2 mouse is prone to
spontaneous expansion and contraction. Indeed, unintended R6/2 sublines exist with ≥350
repeats (72). The typical R6/2 phenotype is a rapid and severe disease, with motor symptoms
onset at approximately 8 weeks of age and life expectancy between 12-15 weeks (65, 66). The
N171-82Q mouse is an alternative transgenic fragment model that addresses many of the
problems associated with the R6/2 mouse: hemizygotes express HTT exons 1-3 with a more
stable 82-residue polyQ tract from a prion promoter, develop motor symptoms at around 10
weeks of age, and have a life expectancy of 24 weeks (64). The genetic landscape in these
models differs considerably from that of HD patients, but they have proved extremely useful in
elucidating pathogenic HD molecular mechanisms and developing novel treatment strategies.
Transgenic full-length HTT models
The difficulty associated with creating transgenic full-length HTT models was solved
using yeast or bacterial artificial chromosomes (YAC or BAC, respectively) (73, 74). Mice created
from both artificial construct types utilize multiple transgene copy number and high CAG triplet
repeat number to induce a phenotype (100 and 126 in the most common YAC model, YAC128;
97 in the BAC model, BACHD), but the presence of the full-length gene imparts higher construct
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validity than transgenic fragment models (73, 74). Additionally, both models contain a small
number of CAA repeats interspersed throughout the CAG tract that prevents both germline and
somatic expansion but still encodes glutamine. However, disease in these mice is more insidious
and they typically do not experience shortened lifespan, making them less convenient for
experimental purposes (75). Additionally, both YAC128 and BACHD mice gain weight over their
lifespans, opposite the weight loss phenotype observed in patients and other HD mouse models,
which makes these models inappropriate for studying systemic phenotypes (76, 77). This
unexpected phenotype correlates with human HTT gene copy in mice—suggesting that human
HTT has slightly different function than the endogenous mouse huntingtin homologue, Hdh—and
may result from IGF1 signaling activation in full-length transgenic mice (77, 78). Nevertheless,
these models have proved especially useful for studying potential therapies targeting the human
HTT gene or protein.
Knock-in models
HD knock-in (KI) models contain a CAG repeat expansion in one or both of the
endogenous mouse HTT alleles, thereby recapitulating HD genetics better than either of the
transgenic models. Expanding the HTT allele in KI models occurs through homologous
recombination, eliminating the confounding factors associated with random transgene integration
and making possible allelic series of mice that differ only in CAG repeat number. As with other
HD mice, though, shorter CAG repeat tracts do not produce robust phenotypes, and many
studies therefore rely on mice with CAG tracts longer than the most expanded human alleles (28,
29). With knock-in lines it is also possible to study mice either heterozygous or homozygous for
the expanded allele; homozygotes tend to have more robust and easily-detectable phenotypes,
but very few HD patients have two mutant alleles, so heterozygous KI mice better replicate the
typical human genetics (79). The phenotypes in the commonly-used heterozygous KI lines
HdhQ150 and zQ175 are insidious onset, slow progression, and no decrease in life expectancy
(80, 81). These mice are the most accurate of all available mouse models, but the relatively mild
phenotype requires large study numbers and thus limits their experimental utility.
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Heart Phenotypes in HD Models
Evidence of heart pathology has been detected in many HD models, though the
mechanisms leading to the phenotypes are not well understood. Heart disease can occur as a
result of intrinsic cardiac abnormalities, abnormal autonomic inputs, and pathology in other
peripheral organs such as the blood vessels, liver, or kidney (82). Consequently, one of the
outstanding questions in studies of HD animal model hearts is which of those etiologies explains
the observations. One of the simplest models studied was a Drosophila melanogaster engineered
to express cardiac-specific polyglutamine (polyQ) peptides containing either 25 (non-pathogenic
control), 46, 72, of 102 residues. Flies expressing the expanded peptides experienced dosedependent functional pathology of dilated chambers, impaired contractility, arrhythmias, and
reduced survival (67). Additionally, on closer inspection the expanded polyQ fly hearts showed
dose-dependent disorganization of myofibrillar structure, mitochondrial pathology, and increased
oxidative stress (67). Similarly, heart-specific expression of an 83-residue polyQ peptide in mice
resulted in dilated ventricles, cardiomyocyte necrosis, inflammation, fibrosis, and decreased
survival compared to mice expressing a 19-residue peptide (68). Though the phenotype
associated with polyQ peptide overexpression likely models amyloidosis better than HD, these
systems suggest that cardiac mHTT expression may cause cardiomyopathy independent of
neuronal or systemic insults.
Though polyQ expression within cardiomyocytes may cause toxicity, studies in more
accurate HD mouse models have presented a more nuanced phenotype. The first study to
examine the heart phenotype in R6/2 mice found diminished size, ventricular wall motion, and
passive ventricular filling, (37). Ultrastructural mitochondrial morphology was also altered, and
though the left ventricles were mildly dilated at necropsy, there was no evidence of fibrosis or
apoptosis at end-stage disease (37). However, later studies have found evidence of mild,
progressive fibrosis in R6/2, homozygous HdhQ150 knock-in (83), Q175 knock-in (84), and
BACHD mice (85). Cardiac MRI studies in the R6/2 mouse confirmed general decreased heart
size in the HD mice, and also found that heart shape gets progressively more distorted and
ventricles become weaker and stiffer than in wild type (WT) littermates (86). Additionally,
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diminished coronary blood flow rate in R6/2 mouse hearts indicates decreased coronary reserve
and increased susceptibility to ischemic injury (86). On a molecular level, R6/2 and HdhQ175
showed increased expression of fetal and pathology-associated genes, together indicative of
ongoing heart pathology (83), and BACHD mouse hearts have increased levels of pro-apoptotic
proteins (85). While certain phenotypic details differ both between mouse lines and between
studies, it is clear that the heart is affected in multiple HD mouse models.
The mechanisms leading to heart abnormalities have been less obvious in HD mouse
models. Similar to HD patients, many studies have implicated autonomic dysfunction as central to
the phenotype. Examination of myocardial electrical activity in the R6/2 and HdhQ150 mouse
indicated heart rate (HR) was slower but more variable in both HD models compared to WT
littermates, with elongated QT, ST, and QTS intervals, suggesting possible long QT syndrome
(83). On histology, the R6/2 and HdhQ150 mice also showed markedly altered ganglionic plexus
structure within the myocardium, and mislocalization of the gap junction protein Connexin 43,
supporting the hypothesis that neural regulation and myocardial conduction are impaired in HD
(83). Weighted gene correlation network analysis in these two models at end-stage disease
suggested that an HD-related global transcriptional dysregulation does not occur in cardiac
tissue, attributing heart pathology to altered neuronal or other systemic inputs (83). The Q175 KI
model also displayed severe autonomic dysfunction, with decreased heart rate variability and
altered circadian rhythms in both heterozygous and homozygous mice, and blunted baroreceptor
response in homozygotes (84). These studies thus confirm autonomic impairment as a factor in
HD, but it is still unclear how altered neuronal regulation contributes to the observed heart
pathology.
Aberrant autonomic heart regulation can result from both CNS degeneration and
cardiomyocyte-specific pathology, and evidence suggests that mHTT expression in HD mouse
models causes cell-autonomous pathology independent of neural inputs. Specifically, chronic
exposure to the β-adrenergic agonist isoprenaline (ISO) failed to induce heart hypertrophy in
R6/2 mice and increased heart failure-associated gene expression (87). Similar ISO exposure in
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BACHD mice causes significantly greater fibrosis than in stressed WT littermates, suggesting that
cardiac mHTT expression sensitizes the heart to stress (85). Additionally, the transcription
profiles of 18 histone deacetylases (HDAC) and sirtuins differed significantly between stressed
R6/2 and WT mice hearts (87). These epigenetic modifiers have key roles in directing the cardiac
hypertrophic response (88-90), and their blunted expression indicates that hypertrophic signaling
is impaired in HD hearts. The mechanisms underlying abnormal stress response are still unclear,
but because ISO acts directly on cardiomyocytes independent of neuronal inputs the effect is
likely linked to mHTT expression in the heart.
One of the factors contributing to the abnormal stress phenotype may be mitochondrial
dysfunction. The ultrastructural mitochondrial morphology in R6/2 mouse hearts was significantly
more circular and less ellipsoid than in WT littermates (37). Additionally, deregulated
mitochondria-associated genes were identified in RNA-seq or microarray analyses of R6/2 (87)
and BACHD (85) hearts, respectively. A detailed metabolic study in R6/2 and homozygous
HdhQ150 mouse hearts found decreased ATP/ADP and NADH/NAD+ ratios, with diminished
phosphocreatine levels, accompanied by elevated purine catabolites—including hypoxanthine,
uric acid, and uridine—in serum from both HD mice and patient samples (91). Metabolic labelling
in HD mouse hearts demonstrated normal glycolysis but impaired Krebs cycle flux, concluding
that mitochondrial dysfunction in HD hearts impairs ATP generation and leads to accumulation of
nucleotide catabolites in serum (91). These bioenergetics abnormalities within HD murine model
hearts are similar to those observed in heart failure (92, 93), so it is difficult to ascertain whether
these changes are a cause or a consequence of the HD animal heart pathology. Nevertheless,
the HD hearts have a clearly diminished energy reserve, which could sensitize hearts to stress
and lead to a unique cardiomyopathy.
Significance and Focus of Dissertation
Clinical evidence indicates that heart disease is one of the leading causes of mortality in
HD patients (40-45). Given the profound neurodegeneration that occurs in HD, clinical studies
have largely focused on neuronal regulation of the heart and found significant dysautonomia (48-
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51), which is recapitulated in HD animal models (83, 84). While altered neuronal control can
adversely affect the heart, preclinical studies have also suggested that mHTT expression within
cardiomyocytes may also contribute to heart abnormalities and lead to a unique form of
cardiomyopathy that includes small heart size, progressive contractile impairment with fibrosis,
and inability to adapt to stress (83-87). The contribution of cardiac mHTT to the heart phenotype
in HD thus remains largely unknown. Additionally, the heart phenotype has been examined on a
functional and tissue level for multiple HD animal models, but very few studies have proposed
underlying molecular mechanisms. Elucidating the pathogenic processes that occur in HD hearts
will inform clinical care to decrease heart-related mortality and improve quality of life for HD
patients. Finally, CNS-directed mHTT-lowering approaches will likely unmask heart phenotypes,
so understanding the cellular mechanisms that contribute to HD heart pathology will be essential
for directing future therapeutic strategies.
In this dissertation, I focus on understanding how cardiac molecular changes in HD lead
to heart-related mortality. I characterize the heart phenotype in two HD mouse models and
propose that cardiac mHTT expression impairs mTORC1 activity, resulting in decreased ability to
adapt to cardiac stress. In Chapter II, I characterize the heart phenotype in the N171-82Q and
heterozygous zQ175 HD mouse models and find that HD mouse hearts have diminished size but
are otherwise functionally normal, suggesting that mHTT expression alone may not be sufficient
to cause heart disease. In Chapter III, I describe diminished mTORC1 activity in HD mouse
hearts, examine the upstream effectors to illuminate the underlying mechanism, and show that
mHTT expression is necessary for mTORC1 dysregulation. In Chapter IV, I show that restoring
mTORC1 activity can alleviate the sensitivity to cardiac stress in HD hearts. Chapter V provides a
summary of the results and discusses implications and future considerations.
Contributions to work presented in this Thesis
This thesis represents work that was, in part, submitted for publication in Cell Reports,
which has been accepted based on reviewer comments. Work contributed by authors other than
DC is indicated in the methods or figure legends.
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CHAPTER 2: CARDIAC PHENOTYPE IN HD MOUSE MODELS
Introduction
CNS-specific HTT-lowering therapies, currently entering or progressing through clinical
trials (32-35), may unmask peripheral phenotypes and present new clinical challenges. HD
patients have relatively high mortality (40-42) of heart disease, but the phenotype in HD patients
is poorly understood for numerous reasons, including a justified focus on the brain, history of
heart disease as an exclusion factor in clinical studies, and limited peripheral tissue collection.
Thus, most of our understanding of an HD heart phenotype is inferred from animal models,
particularly mice.
Efforts to characterize the heart phenotype in HD mice have shown variability between
different models and among different studies using the same model. The challenges associated
with each mouse used must be considered when interpreting results. For example, the R6/2
mouse has been studied more than any other model, but its aggressive metabolic and systemic
phenotypes may confound heart studies (66). The BACHD mouse has better model validity than
transgenic fragment models, but becomes obese with age, thereby displaying the opposite
metabolic phenotype as HD patients (76). Obesity has very well-studied adverse consequences
for the heart (94) and therefore significantly confounds any comparison between hemizygotes
and WT littermates. KI models are likely the most valid HD animal model, but even the most
expanded CAG lines develop the disease slowly and tend to have subtle phenotypes.
Consequently, most heart studies that employ these models used animals homozygous for the
expanded allele, which are more severely affected than heterozygotes but replicate a genetic
landscape uncommon in the HD population.
For my studies, I used two HD mouse models with previously unstudied heart
phenotypes in order to minimize confounding factors and enable the use of previously validated
tools. The majority of my work was done in the N171-82Q model, a transgenic fragment model,
with findings validated in heterozygous zQ175 mice, a knock-in model. The N171-82Q strain has
numerous benefits over the R6/2 mouse including a CAG tract nearly half the length, thereby
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imparting greater generation-to-generation stability and more similar to the human mutation
(though still considerably longer than the average HD patient) (69). Additionally, the phenotype in
N171-82Q mice is less severe than in R6/2 mice but still robustly recapitulates the HD neurologic
and systemic signs (64). Finally, the transgenic fragment in N171-82Q mice is longer than the
fragment expressed by R6/2 mice and therefore contains sequences targeted by validated,
artificial microRNAs (miRNA) to knock down (KD) mHTT, a tool employed in later chapters.
Though useful for experimental purposes, the transgenic nature of N171-82Q means that two
normal mouse Htt alleles are present, so I validated my results in heterozygous zQ175 mice.
I performed a thorough examination of the heart in each mouse model, starting from an in
vivo functional approach and working down to a molecular level, to both better understand the
individual strain phenotypes and to broaden understanding of the HD phenotype. I hypothesized
that, similar to other HD mouse models, hearts would be smaller than in WT littermates. Given
previous results from the R6/2 and HdhQ150 model, I expected to observe progressive
indications of heart failure including fibrosis, apoptosis, and activation of a heart failureassociated gene expression profile.
Results
Cardiac function is normal in HD mouse hearts
Progressive cardiac function and morphology abnormalities have been described in HD
mouse models, though with variation between models. The R6/2 model had decreased cardiac
output secondary to diminished stroke volume and fractional shortening on echocardiogram, as
well as altered ventricular filling dynamics on ex vivo analyses, together indicative of stiff, weak
ventricles (37, 86). Conversely, MRI found smaller heart size in homozygous HdhQ150 but
recorded normal ejection fraction, suggesting normal function but smaller heart size (83).
I determined where 18 week-old N171-82Q (end-stage disease) and 18 month-old
heterozygous zQ175 (symptomatic) mice fit on this functional spectrum by transthoracic
echocardiography. In N171-82Q mice, left ventricular end diastolic (LVEDV, Figure 1A) and
systolic volumes (LVESV, Figure 1B) were decreased, as was estimated left ventricular mass
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(LV mass, Figure 1C) and heart rate (HR, Figure 1D) relative to WT littermates.
Correspondingly, the calculated stroke volume (SV, Figure 1E) and cardiac output (CO, Figure
1F) were also reduced. However, ejection fraction (EF, Figure 1G) and fractional shortening (FS,
Figure 1H) were increased at baseline in transgenic animals relative to WT, suggesting these HD
mice have smaller hearts than their WT littermates but maintain intact ventricular function at endstage disease. zQ715 mice had similar but less pronounced differences as N171-82Q animals. In
the KI mice, LVEDV (Figure 2A) and LVESV (Figure 2B) were decreased, as was estimated LV
mass (Figure 2C). There were no differences in HR (Figure 2D), SV (Figure 2E), CO (Figure
2F), EF (Figure 2G), or FS (Figure 2H). Both HD mouse models thus appear to have diminished
heart size, but EF and FS—general indicators of heart function—are either increased or equal to
WT, suggesting that hearts in these models are not functionally impaired.
HD mouse hearts have decreased gross size compared to WT
Diminished cardiac mass has been reported in multiple mouse models (37, 84, 86) and in
human HD patients at autopsy (46), suggesting that it is a key aspect of the HD heart phenotype.
I confirmed echocardiography measurements by gross examination of HD mouse hearts and
followed changes over time. Excised hearts from N171-82Q mice at end-stage disease were
visibly smaller than their WT littermates but had no apparent morphologic differences such as
ventricular dilation (Figure 3A). When tracked temporally, decreased heart mass in HD relative to
WT mice became apparent at 10 weeks (early-stage disease) and continued to manifest
throughout the study (Figure 3B). The growth curves show that the differences between HD and
WT heart masses result from failure to gain mass around the time of symptom onset, a trend
consistent with the reported pattern of body mass changes in HD patient populations (95).
I normalized heart masses to both tibia length and body mass in order to determine if size
discrepancies between N171-82Q and WT hearts were intrinsic or due to systemic conditions. If
heart mass differences result from lack of growth factors, the tibia length will be decreased and
heart mass to tibia length ratio will be equal between genotypes. Tibia lengths were identical
between HD and WT animals at every time point observed (Figure 4A), and thus heart mass to
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tibia length was decreased starting at 10 weeks and continuing through disease (Figure 4B).
Accordingly, heart growth impairment in N171-82Q animals is not secondary to a lack of growth
factors.
Decreased body mass is common in both HD patients and mouse models, so decreased
heart mass may simply result from negative systemic energy balance. I found reduced body mass
N171-82Q mice, starting before symptom onset and continuing through disease (Figure 5A).
Interestingly, the heart mass-to-body mass ratio does not differ between WT and N171-82Q
animals at 6 weeks (pre-symptomatic) and 10 weeks of age (early-stage disease), but at 14
weeks (mid-stage disease) and 18 weeks of age it is larger in N171-82Q animals relative to WT,
suggesting that the heart mass does not change proportionally with the rest of the body (Figure
5B). Indeed, comparing heart mass and body mass in N171-82Q mice over lifespan shows
relatively constant heart mass while body mass fluctuates (Figure 5C). While it is not possible to
rule out negative energy balance affecting the heart at early time points, the later growth curve
differences suggest that HD mouse heart mass is regulated independent of body mass changes.
Heart mass differences were similar in zQ175 animals at 12 months of age (post
symptomatic). Both heart mass (Figure 6A) and heart mass-to-tibia length ratio (Figure 6B) are
decreased in HD mice relative to WT, with no change in tibia length between genotypes (Figure
6C), confirming conclusions from observations of N171-82Q mouse hearts. Additionally, body
mass was decreased in 12 month-old zQ175 animals (Figure 7A), but there was no difference in
heart mass-to-body mass ratio (Figure 7B), implying that at 12 months zQ175 hearts are still
proportionate to body mass at this time point.
HD mouse cardiomyocyte size is decreased
Based on the observation that HD mouse hearts have limited growth but don’t atrophy
over the course of disease, I hypothesized that HD mouse hearts would have decreased
cardiomyocyte size relative to WT rather than cell loss. I measured cardiomyocyte cross-sectional
area using wheat germ agglutinin staining to identify cardiomyocyte borders (Figure 8A). As
expected, there was no difference in mean cross-sectional area in 6-week-old N171-82Q mice
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relative to WT littermates, but 14-week-old N171-82Q mice and 12-month-old zQ175 mice had
decreased myocardial cross-sectional area relative to WT (Figure 8B-C). These results were
further supported by examining surface area of ex vivo cardiomyocytes isolated from 14 week-old
N171-82Q hearts, which showed smaller surface area than age-matched WT cardiomyocytes
(Figure 9). Based on these data, the size difference between HD and WT hearts appears to
result from reduced cardiomyocyte size.
Loss of cardiomyocytes in HD hearts relative to WT may contribute to gross size
differences, and both the R6/2 and BACHD mouse model have progressive, mild fibrosis,
indicative of cardiomyocyte death (83, 85). In order to determine if similar effects occur in N17182Q and zQ175 hearts, I stained heart sections with Masson’s trichrome but found no evidence of
fibrosis in HD hearts from N171-82Q mice at 6 or 14 weeks of age, or in zQ175 animals at 12
months of age (Figure 10). Additionally, TUNEL staining of 18 week N171-82Q hearts showed no
evidence of apoptosis (Figure 11). Together, these data denote limited cardiomyocyte growth in
HD models accounting for mass differences, not cardiomyocyte loss.
Metabolic changes in HD mice do not explain decreased body mass
Heart and whole body growth curves are different for N171-82Q mice, suggesting that
heart size is regulated independent of body mass (Figure 5C). However, a systemic negative
energy balance—expending more calories than are consumed—may underlie impaired heart
growth. I therefore investigated the body mass phenotype in HD mice on a systems level in order
to identify possible etiologies that could underlie the inhibited heart growth. HD patients and
mouse models have been described as hypermetabolic, losing body weight especially at end
stage disease (96). I used a comprehensive laboratory animal monitoring system (CLAMS) to
analyze metabolic function in HD mice. I examined N171-82Q mice and WT littermates at 9, 13,
and 17 weeks of age, and zQ175 and WT littermates at 12 months of age, and assessed oxygen
consumption (VO2), carbon dioxide production (VCO2), feeding, and activity over the course of 72
hours. Due to circadian regulation of metabolism, I also stratified data into light and dark cycles.
Surprisingly, I found that N171-82Q mice at 13 and 17 weeks of age had lower VO2 and VCO2
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during the light cycle than WT littermates, with no differences during the dark cycle (Figure 12AB), indicating a hypometabolic state during the day. Additionally, N171-82Q were more active
than WT littermates during the light cycle at all time points tested and also during the dark cycle
at 13 and 17 weeks of age (Figure 12C). Feeding patterns were altered in 13 and 17 week-old
N171-82Q mice relative to WT, with no difference in total food consumed per day but altered
timing: HD mice ate less during the light cycle but more during the dark cycle (Figure 12D).
Together, N171-82Q mice had a lower metabolic rate than WT littermates in spite of increased
activity, suggesting that decreased body mass and limited heart growth is not a result of systemic
negative energy balance. However, ambient room temperature was measured to be 18°C
(compared to 22°C normal housing), which may confounded results.
Metabolic measurements in 12 month-old zQ175 mice were similar to those from N17182Q mice. VO2 and VCO2 were decreased during the light cycle compared to WT littermates, with
no difference during the dark cycle (Figure 13A-B). Activity in zQ175 mice was increased relative
to WT during the light cycle, with a similar trending but non-significant increase during the dark
cycle (Figure 13C). Additionally, zQ175 mice food intake trended lower during the light cycle but
was not statistically significant (Figure 13D). While these data recapitulate, in many respects, the
data from N171-82Q mice, the ambient room temperature again was lower than normal housing
rooms and thus should be interpreted cautiously.
Gene expression in HD mice does not indicate ongoing heart pathology
I did not observe functional impairment on echocardiography (Figure 1), but gene
signatures associated with heart failure have been detected in other HD mouse model hearts (83,
85). Typically, these genes sense stress and limit maladaptive changes. Atrial natriuretic peptide
(Anp) and brain natriuretic peptide (Bnp) are hormones expressed in the ventricles (despite their
names) that reduce central venous pressure in response to excessive cardiomyocyte stretching
(97). Anp and Bnp expression were both decreased at 14 and 18 weeks in N171-82Q animals—
opposite the expected findings in cases of heart failure—and BNP expression was also
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decreased at 6 weeks in N171-82Q mice (Figure 14A-B). No differences were observed between
zQ175 and WT hearts at 12 months.
Another set of genes associated with cardiac stress are Fhl1 and Fh2, members of the
Four-and-a-Half-LIM Domain family that are involved in myogenesis, stress sensing, and cardiac
hypertrophy. They are typically expressed only in fetal hearts but are upregulated in cases of
heart failure (98, 99). In N171-82Q hearts, Fhl1 was slightly increased relative to WT at 6 weeks
of age (Figure 15A), though the increase is less than the levels observed in heart failure.
Furthermore, both Fhl1 and Fhl2 were decreased relative to WT at 14 weeks in N171-82Q hearts,
and no differences were observed at either 18 weeks or in 12 month zQ175 animals (Figure 15AB). Together with natriuretic protein expression, these results corroborate the echocardiography
results (Figure 1) and confirm that N171-82Q and zQ175 mice are not experiencing increased
stress.
Although cardiomyocyte apoptosis was not evident by TUNEL staining at 18 weeks
(Figure 11), I queried transcripts encoding the apoptotic factors Bax (pro-apoptotic) and Bcl2
(anti-apoptotic) as a more sensitive indicator. Bax levels were modestly increased in in N171-82Q
hearts relative to WT at 6 and 10 weeks, but were decreased at 14 weeks and not different from
WT at 18 weeks. Thus apoptosis may be mildly activated at early disease stages but not at later
stages (Figure 16A). Additionally, Bax expression in heart failure is typically increased by
multiple fold, whereas the increase observed here is relatively small (100). There were no Bax
differences in zQ175 hearts relative to WT (Figure 16A), nor were there differences in Bcl2
expression at any time point in either mouse model (Figure 16B). These data thus reaffirm the
TUNEL analysis and indicate that apoptosis is only occurring at specific time points and at low
levels, if it is indeed occurring at all.
Finally, I examined general expression markers of heart pathology. Vgl4 and S100a4 are
typically increased in heart disease (101-103), and Serca2a tends to be decreased in unhealthy
hearts (104); these genes also have altered expression in the R6/2 and Q150 HD mouse models
(83). Vgl4 expression was increased at 10 weeks in N171-82Q hearts and 12 month zQ175
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hearts relative to WT, but decreased at 14 weeks and no change at 18 weeks in N171-82Q
hearts (Figure 17A). Additionally S100a4 expression was increased in 6 week and 10 week
N171-82Q hearts relative to WT, with no difference at later stages or in zQ175 hearts (Figure
17B). Serca2a expression did not differ between HD and WT at any time point in either model
(Figure 17C). These expression patterns suggest different disease processes between early and
late disease stages. However, as with other genes analyzed, the modest increase in Vgl4 and
S100a4 expression in HD model hearts are much less than those observed in heart failure. Thus,
taken together these data infer that HD does not necessarily cause heart failure.
Discussion
Heart failure phenotypes have been observed in several HD mouse models (37, 83, 85),
suggesting that mHTT expression in the brain or heart causes cardiac disease. In my studies I
found evidence to suggest that mHTT expression in two HD murine models, N171-82Q and
zQ175, is associated with smaller heart size but may not directly cause pathology.
Echocardiography analysis showed that HD hearts were smaller than WT littermates, but normal
or increased EF and FS indicated lack of functional impairment. Gross analysis similarly showed
diminished size in HD hearts, but no morphologic abnormalities to suggest ongoing pathology.
Furthermore, heart mass appears to be regulated independent of body mass. On histology, cell
area was decreased in HD hearts relative to WT, but there was no fibrosis or apoptotic activity.
Finally, the expression pattern of genes associated with heart disease was not consistent with
ongoing pathology. Thus, while the decreased heart size is an obvious phenotype, these results
seem to indicate that hearts in N171-82Q and zQ175 HD mouse models are not failing. These
observations infer, then, that mHTT expression alone may not be sufficient for pathology.
Echocardiography data was the first indication of absence of heart failure and mimics
results obtained on MRI from the R6/2 and HdhQ150 models, showing decreased chamber size
but normal ejection fraction (83, 86). These metrics alone do not, however, rule out heart failure
with preserved ejection fraction (HFpEF), a form of heart disease characterized by diastolic
dysfunction resulting from impaired ventricular relaxability. While cardiac MRI only showed mildly
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distorted axis in R6/2 mice, the ex vivo pressure analysis supported HFpEF by showing
decreased passive filling and increased atrial filling, indicating stiff, weak ventricles (86). Thus,
morphologic metrics are insufficient to properly diagnose HFpEF and require either
echocardiography with tissue Doppler and/or ex vivo pressure analyses, both of which should be
employed in the N171-82Q and zQ175 models in future studies However, while my
echocardiography studies can’t rule out HFpEF, histology and gene expression analysis showed
a lack of heart pathology, thus disfavoring HFpEF and supporting the more benign phenotype of
small but functional heart.
Though heart mass seems to be regulated independent of body mass, metabolic studies
were performed to determine if a hypermetabolic state could explain changes in heart size.
Indeed, increased basal metabolic rate can lead to a negative energy balance and thus weight
loss. Surprisingly, results showed that HD mice had a similar metabolic rate as WT mice during
the dark cycle but were hypometabolic during the light cycle at later disease stages (Figure 1213). HD mice were also more active relative to WT, especially during the light cycle (when mice
typically sleep) consistent with reports that HD disrupts sleep-wake cycles and circadian
rhythmicity (105). However, it is intriguing that decreased VO2 and VCO2 were observed, even
with this increased activity. Furthermore, this data suggests that if activity were controlled for, the
hypometabolic state observed in the HD animals would be even more severe than what was
observed. This conclusion is puzzling given the weight loss phenotype in HD mice; usually
decreased metabolism is associated with increased body weight. Metabolism in HD is more
nuanced than simply increased or decreased—brain MRI in HD patients revealed striatal
hypometabolism concomitant with cortical and cerebellar hypermetabolism (106)—but the
systemic phenotype doesn’t seem to fit with the metabolic data. One of the leading explanations
for this discrepancy may be the ambient room temperature: for these studies mice housed at
22°C, whereas the metabolic cages were in a room that, due to facility reasons and inability to
control individual room temperatures, was only 18°C. Hypothermia is a well-characterized
phenotype of HD mice linked to impaired brown fat activation (107), and thus being housed in a
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colder-than-normal environment may have aggravated this phenotype and confounded metabolic
regulation. Consequently, these results should be interpreted cautiously.
Heart failure-associated gene expression was generally absent in HD hearts relative to
WT hearts; when changes were present they either occurred in the opposite direction or at a
magnitude significantly lower than that associated with disease. However, while expression
changes may not be physiologically relevant or represent a small subset of cardiomyocytes, in
many instances they occurred only in early stage N171-82Q animals but resolved at later disease
stages. This distinction is relevant because one of the large questions with regard to HTTtargeting therapies is when to begin treatment; in other words, when does the disease start?
There is increasing evidence to suggest that HD has a developmental component (108), and thus
understanding the changes that occur in the premanifest stage are vital to understanding the
whole phenotype.
The lack of apparent heart pathology does not mean there is no phenotype. Small heart
size is clearly apparent in the HD mice studied here, which recapitulates HD patients (46) and
replicates observations from other HD mouse models (37, 84, 86). Unfortunately, the molecular
characteristics of the HD patient heart have not yet been studied, so it is impossible to know if the
histological and gene expression changes—or lack thereof—observed in mice are accurate. The
data I show here suggest that small heart size and mHTT expression may be relatively benign
under the conditions studied, but work in subsequent chapters will explore mechanisms
underlying heart mass regulation in HD animals and conditions in which the phenotype is
detrimental.
Materials and Methods
Animals
All animal protocols were approved by the Animal Care and Use Committee at The
Children’s Hospital of Philadelphia (CHOP). N171-82Q and heterozygous zQ175 HD murine
model lines were obtained from Jackson Laboratories (Bar Harbor, ME) and maintained on a
B6C3F1/J (N171-82Q) or C56B6/J (zQ175) background. Mice were genotyped using primers
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specific for human HTT, and age-matched WT littermates were used as controls for all
experiments. All experiments were performed with male mice exclusively. Animals were housed
in enriched, temperature-controlled environments with a 12-hour light/dark cycle. Food and water
were provided ad libitum.
Transthoracic Echocardiography
All echo procedures were performed at the CHOP Small Animal Imaging Facility. Mice
were anesthetized with 2.5% isoflurane and positioned on a heated stage with continuous EKG
measurement. Transthoracic echocardiograms were recorded using an MS-400 30 MHz probe
connected to a Vevo 2100 or 3100 imager with cardiovascular measurement package. (Fujifilm
VisualSonics). Parasternal long axis views with Doppler were used to calculate aortic ejection
time and mitral valve flow dynamics. Parasternal short axis M-mode views at the level of papillary
muscles were used to calculate posterior wall, septum, and ventricular diameter each at end
diastole and end systole. Images were acquired and dimensions measured by Christine J.
Pascua, an experienced operator blinded to mouse genotype. Stroke volume was calculated as
the difference between left ventricular end diastolic and systolic volumes, and cardiac output
calculated as the stroke volume multiplied by the heart rate.
Heart Mass Analysis
Mice were massed, then anesthetized with a mixture of ketamine/xylazine (IP injection of
100 mg/kg and 10 mg/kg, respectively) and transcardially perfused with cold saline. Whole hearts
were excised with atria intact, blot-dried, and massed on an analytical balance. Left tibias were
removed and measured with electronic calipers to control for variation in total body size.
Histology
Excised hearts were bisected transversely at the approximate midpoint, and apical
portions were post-fixed overnight in 4% paraformaldehyde. Heart tissue was dehydrated and
embedded in paraffin by the CHOP Pathology Core, and sectioned to 5-7 µm. Sections were
originally cut on a sledge microtome (Leica SM2010R), but were later cut on a standard rotary
microtome (Microm HM 355s) because it was determined the retract function—not available on
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the sledge models—significantly prevents artifacts. Mounted sections were heated at 56-60°C for
20 minutes to remove excess paraffin, flatten sections, and prevent detachment. Sections were
allowed to cool to RT and rehydrated before continuing with staining procedures. All sections
were imaged on a Leica DM6000B light microscope.
Masson’s Trichrome stain: sections were incubated in 56°C Bouin’s solution (Sigma) for
10 minutes, followed by staining with Masson’s Trichrome (Sigma) according to standard
procedure. Briefly, tissues were stained with working Weigert’s iron hematoxylin for 5
minutes, rinsed in deionized water, and then stained in Biebrich scarlet-acid fuchsin for 5
minutes. Slides were rinsed in deionized water, fixed in working
phosphotungstic/phosphomolybdic acid solution for 5 minutes, and then immediately
stained with aniline blue solution for 5 minutes. Sections were destained in 1% acetic
acid for 2 minutes, rinsed in deionized water, dehydrated through ethanol, cleared in
xylene, and mounted.
Wheat germ agglutinin: sections were washed twice for two minutes in tap water, then
placed into a solution of 10 µg/ml wheat germ agglutinin and 2 µg/ml Hoechst stain in
PBS. Slides were stained for 15 minutes at 37°C, then washed twice for two minutes in
deionized water and mounted with fluorogel. For quantitative analysis, images were taken
throughout the posterior wall to encompass all transversely-sectioned cells. ImageJ was
used to overlay a grid on each image to randomly select approximately 50 cells/image
and cross-sectional area was measured for each selected cell by either manually
circumscribing the cell exterior or using the threshold function and magic wand tool. At
least 200 cells were measured per heart.
Ventricular cardiomyocyte isolation
12-13 weeks old mice were anesthetized by sodium pentobarbital (50 mg/mL) with
Heparin (55 units/mL) through i.v. injection (1 mL/1 kg). Hearts were excised, perfused
retroaortically (Langendorff), and enzymatically digested with a mixture of collagenase (Type 2)
(Worthington, 250 units/mL), hyaluronidase (Sigma, 0.01%), and protease type XIV (Sigma,
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0.0025%) in a modified Tyrode’s solution (0.1mM CaCl2, 10 mM BDM). Dissociated
cardiomyocytes were washed three times in Joklik MEM (Sigma) with 1 % Pen/Strep and 1X ITS
(Sigma) with increasing Ca2+ (0.25, 0.5, 0.75 mM). Isolated myocytes were cultured with media
consisting a 50:50 mix of DMEM and F10 media with 1% Pen/Strep and 1X ITS. Primary adult
cardiomyocyte isolation was performed by Dr. Olha Koval at the University of Iowa.
TUNEL Stain
Mice hearts were postfixed overnight in 4% PFA, and 6-μm thick sections were collected.
TUNEL staining was performed using TACS® 2 TdT DAB Kit (Trevigen). An investigator blinded
to the mouse genotype and treatments assessed the number of TUNEL-positive cells. Images
were captured using an Olympus BX60 light microscope and DP70 camera with Olympus DP
Controller software.
Metabolic Assessments
Comprehensive laboratory animal monitoring system (Oxymax) was used to measure
systemic metabolic rate in HD and WT mice. Animals were singly-housed in a metabolic cage for
48 hours with continuous monitoring of oxygen input and output, carbon dioxide input and output,
activity, and food. Gas measurements and calculations of VO 2 and VCO2 were made by
calibrated instruments integrated into the system (both represented as ml gas/kg body
mass/hour). Cages were fitted with infrared beam grids that measured activity levels, and food
dispensers were placed on top of scales that measured the mass of food removed. The first 24
hours of data was considered a habituation period and was discarded. Data was stratified
between light cycle and dark cycle because of circadian regulation of metabolism. Statistical
comparisons were calculated between genotypes at the same time point and at the same time of
day.
Quantitative PCR
RNA was isolated using TRIzol (Ambion) according to manufacturer’s protocol. Randomprimed first-strand cDNA synthesis was performed using 2 µg RNA (High Capacity cDNA
Reverse Transcription Kit; Applied Biosystems) according to manufacturer’s protocol. cDNA was
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diluted to 1 ng/µl with DNase/RNase-free water. Quantitative PCR was performed using SYBR
green PCR master mix (Invitrogen) on a real-time CFX384 PCR detection system (Bio-Rad).
Primers were designed with Primer3 using strict prediction parameters (no possibility of primer
dimers, hairpins, or primer pair interaction) or were ordered as predesigned sets (IDT). Manually
designed primers were validated and optimized multiple concentrations for forward and reverse
primers in a standard PCR protocol with template cDNA isolated from a random WT heart. PCR
products were separated by agarose gel electrophoresis, and primers were considered
acceptable if a single, clear band was detected. If multiple bands were detected, or if the single
band were faint even at high concentrations, the primer pair was rejected. Melt curve analysis
was used to further validate primer sets, and primers were rejected if multiple peaks were
present. Primer sequences are listed in table 1.
The 2-ΔΔCt method was used for analysis. Ct values from each gene were normalized to
endogenous expression of a housekeeping gene (ΔCt), then the average values for samples of
interest compared to average values of control samples (ΔΔCt). Multiple housekeeping genes
were assessed over the course of the study and included β-actin, β-tubulin, GAPDH, HPRT,
RPLP0, Cytochrome C, and TATA-binding protein (TBP). TBP was selected for analyses
because Ct values were equal between HD and WT samples both at all time points in N171-82Q
hearts and in zQ175 hearts.
Statistical Analyses
All data was analyzed either by Student’s T-test, with p ≤ 0.05 considered significant.
Statistics were performed in GraphPad Prism version 7.
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Table 1: List of custom-designed primers for chapter 2
Gene Name

Forward Primer

Reverse Primer

Bax

GCAGCTGACATGTTTGCTGATG

AGCCCATGATGGTTCTGATCAG

Bcl2

AGCCTGAGAGCAACCCAATG

CGGTAGCGACGAGAGAAGTC

Fhl1

CTGCCTGAAGTGCTTTGACAAG

AAGCAGTTGTCGTGCCAGTAG

Fhl2

TGGAACCAAGAGCTTCATACCTAAG

GGCTGCTCCCGGTAAGTAAC

Nppa (Anp)

TGGGCTTCTTCCTCGTCTTG

TCATCTTCTACCGGCATCTTCTC

Nppb (Bnp)

TAGCCAGTCTCCAGAGCAATTC

GTGAGGCCTTGGTCCTTCAA

S100a4

GTGTCTTCCTGTCCTGCATTG

CAACACTTCATCTGAGGAGTCTTC

Tbp

TACCGTGAATCTTGGCTGTAAAC

GTTGTCCGTGGCTCTCTTATTC

Vgl4

GAACCGGCCCTCTGTGATTAC

CAGACCCAGGCGCAGAAC

25

Figure 1: N171-82Q hearts have smaller size but normal function on echocardiography.
Heart function in WT (n = 11) and N171-82Q (n = 14) mice at 16 weeks of age (end-stage
disease) measured by transthoracic echocardiography, parasternal short axis, M-mode view.
Results show decreased heart size in HD mice but normal functional. (A) Left ventricular end
diastolic volume (LVEDV); (B) left ventricular end systolic volume (LVESV); (C) left ventricular
(LV) mass; (D) heart rate (HR); (E) stroke volume (SV); (F) cardiac output (CO); (G) ejection
fraction; (H) fractional shortening. Error bars represent standard error of the mean (SEM).
Students T-test; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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Figure 2: zQ175 hearts are smaller but function normally on echocardiography.
Heart function in WT (n = 14) and zQ175 (n = 17) mice at 18 months of age
(symptomatic) by transthoracic echocardiography, parasternal short axis, M-mode view. Similar to
N171-82Q mice, results show decreased heart size in HD animals but normal functional. (A) Left
ventricular end diastolic volume (LVEDV); (B) left ventricular end systolic volume (LVESV); (C)
left ventricular (LV) mass; (D) heart rate (HR); (E) stroke volume (SV); (F) cardiac output (CO);
(G) ejection fraction; (H) fractional shortening. Error bars represent standard error of the mean
(SEM). Students T-test; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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Figure 3: N171-82Q hearts are grossly smaller than WT littermates.
(A) Images of a typical N171-82Q heart juxtaposed with a typical WT heart at excision,
showing clear size discrepancy but no apparent morphological abnormalities. (B) Mass of N17182Q and WT mouse hearts measured at 6 weeks (presymptomatic, n ≥ 6), 10 weeks (early-stage
disease, n ≥ 10), 14 weeks (mid-stage disease, n ≥ 8), and 18 weeks (late-stage disease, n ≥ 8).
Growth curves show that the mass differences are due to failure of N171-82Q hearts to gain
mass relative to WT, not atrophy. Error bars represent SEM. Students t-test, ***p ≤ 0.001.
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Figure 4: Heart size in HD mice is not limited by growth factor availability.
Assessment of (A) tibia lengths, and (B) heart mass to tibia length ratios in N171-82Q
mice and WT littermates at 6 weeks (n ≥ 6), 10 weeks (n ≥ 10), 14 weeks (n ≥ 8), and 18 weeks
(n ≥ 8). Tibia lengths are not different between genotypes at any time point, indicating that limited
heart growth in HD mice is not due to decreased growth factor levels. Error bars represent SEM.
Student’s t-test, ***p ≤ 0.001.
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Figure 5: Heart mass does not change proportional to body mass in N171-82Q mice.
Changes in (A) body mass and (B) heart mass to body mass ratio in N171-82Q mice and
WT littermates. (C) Heart mass and body mass plotted together to show differences in growth
curves. All graphs include data from N171-82Q and WT mice at 6 weeks (n ≥ 6), 10 weeks (n ≥
10), 14 weeks (n ≥ 8), and 18 weeks of age (n ≥ 8). Results show decreased body mass in N17182Q mice relative to WT starting before symptom onset and continuing through disease, with
proportional heart mass at early stages. At later stages, body mass decreases but spares the
heart. Error bars represent SEM. Student’s t-test, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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Figure 6: Heart size is decreased in symptomatic zQ175 mice.
(A) Heart mass, (B) heart mass-to-tibia length ratios, and (C) tibia length in 12 month-old
(symptomatic) heterozygous zQ175 mice (n = 12) and WT littermates (n = 12). Similar to N17182Q mice, 12 month-old zQ175 mice have smaller heart mass and heart mass-to-tibia length
ratios, with no difference in tibia lengths, suggesting that smaller heart mass is not secondary to
lack of growth factors. Error bars represent SEM. Students t-test, **p ≤ 0.01, ***p ≤ 0.001.
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Figure 7: Heart size in zQ175 mice is proportional to body mass.
(A) Body mass and (B) heart mass-to-body mass ratio in in heterozygous, 12 month-old
zQ175 mice (n = 12) and WT littermates (n = 12). At this time point, zQ175 mice weigh less than
WT littermates, with heart mass proportional to body mass. Error bars represent SEM. Students ttest, **p ≤ 0.01.
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Figure 8: Cardiomyocyte cross-sectional area is decreased in symptomatic HD mouse
hearts.
(A) Representative wheat germ agglutinin-stained sections from N171-82Q mice at WT
littermates at 6 and 14 weeks of age, and from zQ175 mice and WT littermates at 12 months of
age. Scale bars = 20 µm. (B) Calculation of cardiomyocyte cross-sectional area in N171-82Q and
WT hearts at 6 weeks (n = 4 for each group) and 14 weeks of age (n = 6 for each group). (C)
Cardiomyocyte cross-sectional area calculated for zQ175 (n = 8) and WT (n = 6) mouse hearts at
12 months of age. Data show reduced cross-sectional area in HD hearts in N171-82Q hearts at
14 weeks of age and in zQ175 hearts at 12 months of age, mirroring heart mass observations.
Mean cross-sectional area for each heart was calculated from > 200 cardiomyocytes. Student’s ttest, **p ≤ 0.01, ***p ≤ 0.001.
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Figure 9: Isolated N171-82Q cardiomyocytes have decreased surface area.
Transillumination confocal microscopy image of cardiomyocytes isolated from 14 weekold N171-82Q and WT littermates. Surface area is decreased in cells from HD mouse hearts (n =
27 cells) relative to WT littermates (n = 30 cells). N = 3 mice/genotype. Error bars represent SEM.
Student’s t-test, ***p ≤ 0.001. Samples were imaged and measured by John Lee.
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Figure 10: N171-82Q and zQ175 mouse hearts are not fibrotic.
Masson’s trichrome staining in sections from N171-82Q and WT mouse hearts at 6 (n =
4/group) and 14 (n = 6/group) weeks of age, and from zQ175 and WT mouse hearts at 12 months
of age. Nuclei stain black, muscle tissue stains red, and collagen (fibrosis) stains bright blue. No
fibrosis was observed in either HD or WT hearts, in either mouse line, and at any time point.
Scale bars = 40 µm.
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Figure 11: N171-82Q mouse heart sections do not show evidence apoptosis.
Representative TUNEL staining in 18 week-old N171-82Q mouse heart sections (n = 4)
and positive control showing complete absence of positive-staining cells in late-stage HD mouse
heart. Apoptotic nuclei stain black. Scale bars = 50 µm. Sections were stained and imaged by
John Lee.
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Figure 12: Longitudinal metabolic analysis of N171-82Q mice.
Comprehensive laboratory animal monitoring system (CLAMS) cages were used to
measure metabolic state in N171-82Q animals at 9 weeks (n ≥ 6), 13 weeks (n ≥ 3), and 17
weeks (n ≥ 6). (A) Oxygen consumption (VO2) is decreased in HD mice at 13 and 17 weeks of
age during the light cycle only. (B) Carbon dioxide production (VCO 2) is decreased in HD mice at
13 and 17 weeks during the light cycle only. (C) HD mice are more active than WT mice during
the light cycle at all time points measured, and during the dark cycle at 13 and 17 weeks of age.
(D) HD mice eat less than WT mice during the light cycle, but eat more during the dark cycle,
leading to no difference in total daily caloric intake. Error bars represent SEM. Student’s t-test, *p
≤ 0.05.

37

Figure 13: Metabolic analysis of 12 month-old zQ175 mice.
Metabolic readouts were measured in 12 month-old zQ175 mice (n = 3) and WT
littermates (n = 3). (A) VO2 is decreased in HD mice during the light cycle but not the dark cycle
relative to WT littermates. (B) VCO2 is decreased in HD mice during the light cycle but not the
dark cycle relative to WT littermates. (C) HD mice are more active than WT littermates during the
light cycle and have a non-significant increase in activity during the dark cycle. (D) HD mice have
a non-significant decrease in food intake during the light cycle relative to WT littermates. Error
bars represent SEM. Student’s t-test, *p ≤ 0.05.
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Figure 14: Cardiac wall stress-related genes are decreased in HD mice.
Quantitative PCR analysis of genes typically upregulated with cardiac wall stress in
N171-82Q mouse hearts at 6 (n ≥ 6), 10 (n ≥ 7), 14 (n ≥ 8), and 18 (n ≥ 8) weeks of age, and in
zQ175 mice at 12 months of age (n ≥ 10): (A) Anp, and (B) Bnp. Both Anp and Bnp expression is
decreased at 14 and 18 weeks in N171-82Q mouse hearts relative to WT, and Bnp is also
decreased at 6 weeks. No differences exist between zQ175 and WT mouse hearts. All genes
were normalized to TATA-binding protein (Tbp) as an internal control and are graphed relative to
WT. Error bars represent the SEM. Student’s t-test, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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Figure 15: Fetal gene expression is not significantly altered in HD mice.
Quantitative PCR analysis of two fetal genes that are reactivated during heart failure, (A)
Fhl1, and (B), Fhl2. Expression was queried in N171-82Q mouse hearts at 6 (n ≥ 6), 10 (n ≥ 7),
14 (n ≥ 8), and 18 (n ≥ 8) weeks of age, and in zQ175 mice at 12 months of age (n ≥ 10). Mildly
increased Fhl1 expression was detected in N171-82Q hearts at 6 weeks, but its magnitude is less
than that observed in heart failure; additionally, Fhl1 and Fhl2 expression are decreased in N17182Q hearts at 14 weeks and otherwise not different, suggesting expression of these genes are
not altered at a physiologic level and implying that cardiac remodeling is not occurring in HD
mouse model hearts. All genes were normalized to TATA-binding protein (Tbp) as an internal
control and are graphed relative to WT. Error bars represent the SEM. Student’s t-test, *p ≤ 0.05,
**p ≤ 0.01, ***p ≤ 0.001.
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Figure 16: Apoptosis genes are elevated only in early-stage N171-82Q mice.
Quantitative PCR analysis of genes associated with apoptosis in N171-82Q mouse
hearts at 6 (n ≥ 6), 10 (n ≥ 7), 14 (n ≥ 8), and 18 (n ≥ 8) weeks of age, and in zQ175 mice at 12
months of age (n ≥ 10): (A) the pro-apoptotic factor Bax, and (B) the anti-apoptotic factor Bcl2.
Early-stage N171-82Q hearts have mildly but significantly elevated Bax, but otherwise no
expression differences are present between HD and WT mouse hearts. Thus, a low level of
apoptosis may occur at early-stage disease but resolves in later stages. Error bars represent the
SEM. Student’s t-test, *p ≤ 0.05, ***p ≤ 0.001.
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Figure 17: Cardiac pathology-associated genes are only elevated in early-stage N171-82Q
hearts.
Quantitative PCR expression of genes associated with heart pathology in N171-82Q
mouse hearts at 6 (n ≥ 6), 10 (n ≥ 7), 14 (n ≥ 8), and 18 (n ≥ 8) weeks of age, and in zQ175 mice
at 12 months of age (n ≥ 10). (A) Vgl4 and (B) S100a4 are generally upregulated with heart
disease, whereas (C) Serca2a expression generally drops. In HD hearts there is mild but
significant upregulation of Vgl4 and S100a4 at early N171-82Q stages and in symptomatic zQ175
mice, but the changes resolve in N171-82Q hearts at later stage disease. Error bars represent
the SEM. Student’s t-test, *p ≤ 0.05, ***p ≤ 0.001.
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CHAPTER 3: MTORC1 DYSREGULATION IN HD MOUSE HEARTS
Introduction
Diminished heart size observed in HD mouse models was not necessarily associated
with heart failure, but the heart’s body mass-independent regulation suggested a cell-intrinsic
mechanism that may have other adverse consequences. One of the key regulators of heart size
and stress response is mechanistic Target of Rapamycin complex 1 (mTORC1), a serinethreonine kinase that integrates multiple environmental cues and promotes cellular growth and
metabolism (109). Conditions favorable to growth promote mTORC1 activity by signaling through
growth factors and nutrient-sensing mechanisms; conversely, settings in which resources are
limited, such as hypoxia and starvation, inhibit mTORC1 activity (109). Multiple downstream
cellular mechanisms are regulated by mTORC1 phosphorylation, including activation of global
translation (110, 111), cholesterol biosynthesis (112, 113), nucleotide biosynthesis (114, 115),
mitochondrial and ribosome biogenesis (116, 117), and inhibition of autophagy (118). Thus,
diminishing mTORC1 activity attenuates cellular growth pathways and activates survival
mechanisms.
In the heart, mTORC1 seems to be most critical during the prenatal period, as abolishing
mTORC1 activity by ablating the activating subunit of mTORC1, Rheb, caused defective
cardiovascular development (119). Additionally, cardiac-specific Rheb knock-out (KO) mice had
reduced cardiac mRNA translation, retarded cardiomyocyte growth, and impaired cardiac function
during the early postnatal period (120). In the adult heart, mTORC1 more expendable but still has
a vital role in maintaining heart function (121) and responding to stress (122, 123). Given its role
in promoting growth, mTORC1 dysregulation is an attractive potential mechanism to explain the
small heart phenotype in HD mice.
mTORC1 activity has previously been studied in the context of HD, but findings among
different studies have not always agreed. mHTT aggregates in HD cells are cleared primarily by
autophagy, and indeed, inducing autophagy with the mTORC1 inhibitor rapamycin limited
aggregate number and improved neuropathology particularly when administered before symptom
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onset (124). Interestingly, the N-terminal domain of mTOR—the mTORC1 catalytic subunit—
forms an extended superhelical solenoid due to multiple HEAT motifs, similar to HTT (125, 126).
mTOR was also found to be sequestered in mHTT aggregates, though how it affects its activity is
not well understood (124). In R6/2 mouse skeletal muscle, mTORC1 is inappropriately increased
and may contribute to atrophy in that setting (127). Furthermore, mTORC1 activity is upregulated
in multiple HD cell models, and restricting its activity improved in vitro pathologic phenotypes
(128, 129). However, mTORC1 activity is decreased in brains from both HD patients and HD
rodent models starting at an early time point (130). Furthermore, restoring mTORC1 activity to
WT levels in HD mouse skeletal muscle and brain alleviated pathology, implying that mTORC1
activity in HD is both tissue-specific and has a central role in the phenotype.
Given mTORC1’s importance in heart size and stress adaptation, mTORC1 activity may
be compromised in the HD heart, which could limit heart growth and potentially cause phenotypic
changes that predispose the development of cardiomyopathy. Considering the diminished heart
size in HD mice and mTORC1 observations in HD mouse brains, I hypothesized that mTORC1
activity would be decreased in HD mouse model hearts. Additionally, given that heart mass
regulation seems to be independent of body mass, I hypothesized that cardiac mTORC1
dysregulation would result as a consequence of cell-intrinsic mHTT expression.
Results
mTORC1 activity is decreased in HD mouse hearts
I analyzed mTORC1 activity by assessing phosphorylation of two downstream mTORC1
targets, ribosomal protein S6 (phosphorylated form abbreviated P-S6) and initiation factor 4E
binding protein 1 (4EBP1, phosphorylated form abbreviated P-4EBP1). Functionally, mTORC1mediated phosphorylation of these proteins enhances activity of S6 and inhibits the inhibitory
4EBP1, together leading to a global increase in protein translation (109). However, mTORC1’s
downstream pathways—including translation—are also subjected to other regulators. Thus, for
the purposes of this work, levels of P-S6 and P-4EBP1 serve only as indicators of mTORC1
activity.
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In HD mouse model heart lysates, P-S6 and P-4EBP1 were decreased relative to WT at
every time point analyzed, starting at the presymptomatic stage (6 weeks old) in N171-82Q mice
and continuing throughout the life of the animals. (Figure 18A-C). P-S6 and P-4EBP1 were also
decreased in 12 month-old zQ175 mice relative to age-matched WT littermates (Figure 18A-C),
thus indicating decreased cardiac mTORC1 in both HD mouse models tested. To further confirm
mTORC1 inhibition, I used immunohistochemistry (IHC) to identify P-S6 in heart sections from
N171-82Q mice at 6 and 14 weeks of age, and from zQ175 mice at 12 months of age.
Interestingly, in age-matched WT mice P-S6 stained positively at what appear to be the
intercalated discs between adjacent cardiomyocytes (Figure 19). Consistent with WB results, PS6 staining in sections from both N171-82Q and zQ175 mice was considerably less dense than
the WT controls (Figure 19). Thus, decreased cardiac mTORC1 activity can be observed on a
histologic level.
mHTT knock-down by RNA interference in HD hearts restores mTORC1 activity
Multiple environmental signals regulate mTORC1 activity, and though the brain is
relatively protected from these signals, cardiac mTORC1 is susceptible to changes in nutrients,
growth factors, or oxygen (131). Thus, the dysregulated cardiac mTORC1 in HD animals may
result from systemic cues or it may be a cell-intrinsic effect. Furthermore, while mHTT expression
has been confirmed in the heart (8, 9), the R6/2 mouse did not have any cardiac mHTT
aggregates (83). However, a considerable body of evidence suggests that aggregates associated
with neurodegenerative diseases may be relatively inert, or even protective, with toxicity occurring
as a result of soluble conformers (132, 133). Thus, the question of how mHTT expression affects
the heart is still unknown.
In order to determine the necessity of mHTT for mTORC1 dysregulation, I employed a
novel, cardiotropic adeno-associated virus (AAV) developed in the Davidson lab, termed CT.AAV.
This vector is a variant of AAV serotype 2 containing a nine amino acid peptide sequence
inserted into its cap gene that imparts strong specificity for cardiomyocyte transduction (Figure
20). I used CT.AAV to deliver a HTT-targeting miRNA expression system developed by the
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Davidson lab (134), termed mi2.1, to knockdown (KD) mHTT in N171-82Q mouse hearts.
Because mi2.1 is human specific, it does not affect endogenous mouse Htt. For controls I used
either formulation buffer (FB) or a CT.AAV delivering a scrambled miRNA control sequence
(miCTRL). I observed 40% mHTT knockdown at the RNA level (Figure 21A) and 35% mHTT
knockdown at the protein level (Figure 21B-C) in hearts from mice injected with CT.AAV.mi2.1.
Analysis of mTORC1 activity indicators showed no difference in P-S6 or P-4EBP1 levels between
hearts of FB- and CT.AAV.miCTRL-injected mice, but showed a significant increase in both
indicators in hearts from mice injected with CT.AAV.mi2.1 (Figure 22A-C). From these data I
conclude that cardiac mHTT expression is necessary for mTORC1 dysregulation in HD hearts.
Modest overexpression of mHTT in WT hearts does not impair mTORC1 activity
Based on the results from mHTT KD studies, I next hypothesized that mHTT is sufficient
for mTORC1 dysregulation in the heart. To test this, I utilized CT.AAV to express the pathogenic
N171-82Q HTT fragment in the hearts of WT mice. For controls I expressed either eGFP or a
non-expanded N171-12Q HTT fragment. I measured the effects against FB-injected mice.
Though CT.AAV is remarkably cardiotropic, I further limited expression of the transgene by
driving expression with a chicken troponin T (cTnT) promoter. I confirmed expression of the
constructs by qPCR (Figure 23A-B) and found that expression of the N171-12Q and N171-82Q
fragments were similar. Notably, both were considerably less than the expression levels of the
mHTT fragment in N171-82Q transgenic mice (approximately 20% of transgene levels). mTORC1
activity as measured by western blot for P-S6 and P-4EBP1 was not different between groups
(Figure 24A-C). I conclude that the relatively low levels of transgene expression preclude my
making any solid conclusions on the sufficiency of mHTT expression for lowering mTORC1
activity.
Growth factor signal transduction is not impaired in HD mouse hearts
The mTORC1 activation pathway integrates multiple cellular signals that can either
promote or inhibit mTORC1 activity (Figure 25). Cardiac mHTT knockdown suggested that
mTORC1 dysregulation in HD mouse hearts is a cell-intrinsic effect, but other systemic cues may
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contribute to the phenotype as well. In order to further confirm the cell-autonomous role of cardiac
mHTT in decreasing mTORC1 activity and to better understand the mechanism by which it
occurs, I performed a battery of assays examining the mTORC1 upstream signaling pathway to
pinpoint at what step dysregulation occurs.
I started my approach considering extracellular factors that could impact mTORC1
activity. The mTORC1 activation pathway is stimulated by receptor tyrosine kinases (RTK), many
of which are growth factor receptors, and the ensuing PI3K/Akt/mTOR signaling cascade (135). I
thus examined the levels of insulin-like growth factor 1 (IGF-1) in HD mouse serum. Surprisingly,
IGF-1 was increased in N171-82Q mice at 6 weeks of age, despite the decreased cardiac
mTORC1 activity, suggesting that increased growth factor may be a systemic compensatory
response (Figure 26A). IGF-1 levels were not different between N171-82Q and WT mice at 14
weeks of age, and slightly but significantly decreased in 12 month-old zQ175 mice, which may
contribute to the mTORC1 dysregulation in these animals (Figure 26A). I next considered serum
insulin levels, another mTORC1-activating signal (131), and found no difference between HD and
WT in either 6 week-old N171-82Q or 12 month-old zQ175 mice (Figure 26B). I did find,
however, that serum insulin was decreased in 14 week-old N171-82Q mice (Figure 26B), but
none of the mice were fasted prior to serum collection, and serum was taken during the light cycle
when N171-82Q mice eat significantly less than WT littermates (Figure 12). Thus, changes in
IGF-1 or insulin levels likely do not explain the significant cardiac mTORC1 dysregulation in HD
mice.
I next considered impaired extracellular signal transduction as a possible mechanism
underlying the mTORC1 abnormalities. To this end, I examined expression levels of the IGF-1
receptor gene (Igf1r) in HD and WT mouse hearts. Cardiac Igf1r levels were not different from
WT in 6 week-old N171-82Q mice and in 12 month-old zQ175 mice, but they were mildly but
significantly increased in N171-82Q mice relative to WT starting at 10 weeks of age and
continuing throughout disease course (Figure 26C). It is possible that this upregulation occurs as
a compensatory mechanism, as normally it would be expected to increase mTORC1 signaling. In
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order to identify potential RTK functional abnormalities, I examined Erk phosphorylation, the end
target of an RTK signaling cascade separate from the PI3K/Akt/mTOR axis. There were no
differences in cardiac Erk phosphorylation between HD and WT in any of the N171-82Q time
points tested or in 12 month-old zQ175 mice (Figure 27A-C). Normal Erk activation implies that
RTK signaling is not impaired, either by lack of extracellular signals or by intrinsically limited
function.
Finally, I measured phosphatase and tensin homologue (Pten) expression, a protein that
functions as an early inhibitor of PI3K/Akt/mTOR signal transduction (109). In N171-82Q mouse
hearts, Pten was mildly but significantly increased at 6 weeks relative to WT; however, at 10
weeks of age, Pten expression was slightly decreased relative to WT, and it was normal at later
N171-82Q time points and in 12 month-old zQ175 mouse hearts (Figure 28). While statistically
significant, the early changes in N171-82Q hearts are so slight that they are unlikely to be
physiologically relevant. Together, these data suggest that RTK signaling is not impaired in HD
mouse hearts, and therefore it does not underlie cardiac mTORC1 dysregulation.
Intracellular mTORC1 signaling is affected in early-stage HD mouse hearts
Because extracellular signals and signaling could not explain dysregulated mTORC1, I
next considered intracellular possibilities (Figure 25). I assessed activity of 3-phosphoinositidedependent protein kinase-1 (PDK1), the downstream target of PI3K, by measuring levels of
phosphorylated Akt (P-Akt); similarly, I assessed activity of Akt by measuring levels of
phosphorylated mTOR (P-mTOR). In hearts from 6 week-old N171-82Q mice and 12 month-old
zQ175 mice, levels of P-Akt and P-mTOR were both decreased relative to WT (Figure 29A-C). At
later time points in N171-82Q mouse hearts, though, levels of P-Akt and P-mTOR normalized and
were not different from WT (Figure 29A-C). These results suggest that in presymptomatic and
early disease stages, mTORC1 dysregulation results from decreased activity of the signaling
cascade. At later stages, however, a separate inhibitory mechanism takes over.
Cellular energy deficiency activates numerous mechanisms that preserve resources and
limit growth, and often include mTORC1 inhibition. Though HD mouse model hearts seem to be
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protected from the processes underlying body mass loss (Figure 5), a cardiac-specific energy
deficiency may contribute to cardiac mTORC1 inhibition. I therefore examined two mechanisms
that inhibit key steps in the PI3K/Akt/mTOR signaling cascade, the adenosine monophosphateactivated protein kinase (AMPK) and FoxO pathways. When adenosine triphosphate (ATP) levels
are low—from starvation, inefficient oxidative phosphorylation, high energy demands, etc.—
cellular mechanisms can convert two molecules of adenosine diphosphate (ADP) into a molecule
of AMP and a molecule of ATP. AMP binds to the AMPK complex, exposing a phosphorylation at
a site on AMPK subunit α (AMPKα) necessary for its activation (136). As AMPK inhibits the
PI3K/Akt/mTOR signaling cascade, I measured levels of phosphorylated AMPKα (P-AMPKα) in
HD and WT mouse hearts but found no differences at any time point in N171-82Q mice or in 12
month-old zQ175 mice (Figure 30A-B). These results infer that HD mouse hearts are not
experiencing acute energy imbalance from starvation or other mechanisms, and AMPK does not
contribute to mTORC1 dysregulation in HD mouse hearts.
A second cellular mechanism that responds to energy stress is the forkhead box protein
O (FoxO) transcription factor family, a more chronic pathway that coordinates expression of
genes that generally oppose the downstream functions of mTORC1 (137). Gene targets of the
FoxO family include gene products that contribute to muscle atrophy, as well as Bnip3, a known
inhibitor of Rheb, the activating subunit of mTORC1 (138, 139). Furthermore, recent reports have
associated HD with increased FoxO3 expression in the brain (140). In HD mouse hearts, FoxO1
expression was elevated relative to WT in both in N171-82Q hearts starting at 6 weeks and in
zQ175 mouse hearts at 12 months (Figure 31A). FoxO3 expression was elevated only in N17182Q hearts at 14 and 18 weeks (Figure 31B). However, expression of Bnip3 in HD hearts did not
differ from WT at any time point in N171-82Q mice or in zQ175 hearts (Figure 31C). While
increased FoxO1 and FoxO3 may indicate chronic energy stress, it is not sufficient to increase
expression of the effector protein Bnip3 and thus the FoxO pathway does not underlie cardiac
mTORC1 dysregulation in HD mice.
Mislocalized Rheb may explain mTORC1 dysregulation in later-stage HD mouse hearts
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While abnormal signal cascade activation was observed in presymptomatic N171-82Q
and in 12 month-old zQ175 mouse hearts, none of the pathways analyzed were different from WT
in later-stage N171-82Q mouse hearts. The PI3K/Akt/mTOR signaling cascade represents a key
mechanism of mTORC1 regulation, but equally important is mTORC1’s subcellular localization. In
the presence of amino acids, particularly branched chain amino acids (BCAA), mTORC1 is
localized to cell endomembranes; this step is critical, as removing amino acids even with
abundant growth factors fails to activate mTORC1 (141). Subcellular localization of many proteins
is affected in HD (142-145), so I hypothesized that decreased mTORC1 activity may result from
improper localization of mTORC1 subunits.
In order to determine if mislocalization of the mTORC1 complex itself underlies its
diminished activity, I delivered a BCAA cocktail to N171-82Q mice and WT littermates by daily
intraperitoneal injection for six weeks (146). Interestingly, there was no difference in P-S6 or P4EBP1 levels between any of the groups, though the BCAA-injected groups from both genotypes
had considerably more variation and seemed to have a slight though statistically insignificant
increase in P-S6 levels compared to saline-injected groups (Figure 32A-C). These results are not
very specific, but they do help to rule out insufficient BCAA as a reason for cardiac mTORC1
dysregulation in HD mice.
The reason mTORC1 localization is essential for its activity is because Rheb, its
activating subunit and the end target of the PI3K/Akt/mTOR cascade, is an integral membrane
protein anchored to cellular endomembranes (147). If Rheb is mislocalized, then mTORC1 will
remain inactive even in the presence of ample amino acids and growth factors (148, 149). I
therefore performed a membrane extraction on 16 week-old N171-82Q mouse hearts and found
that Rheb, the activating subunit of mTORC1, was increased in the cytoplasmic fraction and
decreased in the membrane fraction relative to age-matched WT mouse hearts (Figure 33A-B).
Rheb localization did not differ between N171-82Q and WT hearts at 6 weeks of age (Figure
34A-B) or between zQ175 and WT hearts 12 months of age (Figure 35), consistent with previous
results showing differences in mTORC1 dysregulation between presymptomatic or early-stage
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HD mice and late-stage HD mice. Altering Rheb’s ability to properly localize has previously been
shown to inhibit mTORC1 activity, and thus Rheb mislocalization may underlie the impairment of
mTORC1 in symptomatic HD mice hearts.
Discussion
One of the more common phenotypes that exists in multiple HD mouse models and in HD
patients is diminished heart size, and understanding the underlying molecular mechanisms could
help clarify the phenotypic variability between mouse models and identify why HD patients have a
high risk of cardiac-related mortality. In this chapter, I propose that mHTT expression in
cardiomyocytes leads to cardiac mTORC1 dysregulation. mTORC1 activity was decreased in HD
mouse hearts from both N171-82Q and zQ175 lines. Additionally, cardiac mHTT expression is
necessary for this dysregulation, as miRNA-targeted mHTT KD significantly increased mTORC1
activity in HD hearts. Efforts to discover the mechanism connecting mHTT expression and
attenuated mTORC1 activity showed different etiologies between early and later stages in HD
mice: presymptomatic N171-82Q mice and zQ175 mice both experience decreased
PI3K/Akt/mTOR signaling cascade activity, whereas later-stage N171-82Q mice have normal
upstream signaling but mislocalized Rheb. Decreased cardiac mTORC1 activity in HD mice is
consistent with an absence of heart pathology, given that mTORC1 is not critical for the healthy
adult heart. However, it could predispose to the heart to cardiomyopathy and mortality under
stress conditions (122, 123). The consequences of diminished cardiac mTORC1 activity are
considered in Chapter 4.
While heterozygous zQ175 mice display clear motor symptoms and decreased body
mass, their cardiac molecular phenotype tends to correlate best to a time point between 6 weekold and 10 week-old N171-82Q mice. Considering zQ175 heterozygotes experience symptom
onset around 8 or 9 months of age, and live past 24 months of age, it is reasonable that they
resemble a fairly early disease stage. Importantly, these observations extend beyond examination
of the mTORC1 pathway: in Chapter 2, 12 month-old zQ175 mice were generally most similar to
6 or 10 week-old N171-82Q mice in qPCR analyses of heart failure genes (Figures 14-17),
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though differences in those analyses were much more subtle. The molecular similarities between
young N171-82Q and 12 month-old zQ175 mice are much more apparent when comparing
mTORC1 pathway dysregulation.
Knockdown of mHTT in HD mouse hearts was clearly associated with increased cardiac
mTORC1 activity, permitting me to conclude that cardiac mHTT expression is necessary for the
decreased mTORC1 phenotype. Conversely, overexpression of mHTT in WT hearts did not have
an effect on mTORC1 activity, with P-S6 and P-4EBP1 levels similar across all groups. These
data hint that cardiac mHTT expression alone may not be sufficient to dysregulate mTORC1—an
intriguing hypothesis given the large body of work detailing abnormal CNS inputs to the heart—
but limited transgene expression prevents any conclusion. Though the benign and pathogenic
HTT transgenes were expressed at similar levels, it was only about 20% the expression of the
N171-82Q transcript in transgenic mice, and therefore likely too low to cause a measurable
phenotype within the experimental timeframe. If mHTT expression were increased, or if the
experiment were allowed to proceed longer, it may result in a phenotype similar to that seen in
N171-82Q, or it may be that other systemic factors truly are required in addition to mHTT
expression to generate a phenotype. However, these questions cannot be answered with the
data here. Ideally, future work will confirm the necessity and sufficiency of cardiac mHTT
expression for mTORC1 dysregulation in HD mouse hearts using either a conditional Cre/LoxP or
CRISPR system to completely ablate or express mHTT in cardiomyocytes.
Similar to studies in brain (130), cardiac mTORC1 activity was dysregulated before motor
symptom onset, suggesting that molecular pathogenesis associated with mHTT expression
begins early and contributes to the notable, limited heart growth. Interestingly, the cause of
mTORC1 dysregulation results from distinct etiologies based on disease stage. Presymptomatic
and early-stage mTORC1 dysregulation is associated with decreased PI3K/Akt/mTOR activation,
whereas upstream signaling activity is normal in later-stage HD mice. RTK function was normal in
6 week-old N171-82Q and 12 month-old zQ175 hearts as evidenced by normal P-Erk levels, but
decreased P-Akt suggests signaling is likely impaired at the level between the RTK and PDK1.

52

PDK1 becomes active when it localizes to the cell membrane at phosphoinositides (131), an
interesting similarity when considering that subcellular localization abnormalities may also explain
later-stage mTORC1 dysregulation. Further work deciphering this mechanism should therefore
examine levels of various phosphoinositides in the cell membrane, and determine if PDK1
localization is impaired in early-stage HD mouse hearts.
The mTORC1 dysregulation in mid- to late-stage N171-82Q mouse hearts, even when
upstream signals are normal, is likely due to Rheb mislocalization. Rheb is post-translationally
modified with a farnesyl group that targets it to the cellular endomembranes in the ER, Golgi,
mitochondria, and late endosomes/lysosomes (141, 147). Inhibiting this process induces Rheb
mislocalization and impairs mTORC1 activity (148, 149). Farnesyl is a metabolic precursor
product in the cholesterol biosynthesis pathway, a process impaired in HD (150, 151), and
lysosomal cholesterol stores are also essential for proper mTORC1 localization and activation
(152). While it is still unknown if Rheb in HD hearts mislocalizes due to lack of farnesylation or
through another mechanism, it is possible that aberrant cholesterol metabolism in HD may
contribute to the decreased mTORC1 activity observed in both the heart and the brain.
The failure of BCAA injections to increase mTORC1 activity is a non-specific result, but it
supports Rheb mislocalization as the reason for decreased mTORC1 activity in later-stage HD
animal hearts: if Rheb is not present at the cellular endomembranes, BCAA treatment would be
expected to result in membrane-associated but inactive mTORC1. However, other factors may
also contribute to the observed lack of effect. For one, the BCAA cocktail may not have been
concentrated enough to induce an effect in adult mice. It may also be the case that both HD and
WT mice are eating enough that supplementing BCAA has little effect. Whatever the case, Rheb
mislocalization is a promising mechanism to explain mTORC1 dysregulation in late-stage HD
hearts, and, potentially, the brain. Future work should thus focus on confirming the phenotype in
later-stage zQ175 mice (around 2 years old), applying in vivo cholesterol precursor labeling to
determine whether it results from impaired farnesylation, and examining if Rheb is similarly
mislocalized in HD brain samples.
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Materials and Methods
Animals
All animal protocols were approved by the Animal Care and Use Committee at The
Children’s Hospital of Philadelphia (CHOP). N171-82Q and heterozygous zQ175 HD murine
model lines were obtained from Jackson Laboratories (Bar Harbor, ME) and maintained on a
B6C3F1/J (N171-82Q) or C56B6/J (zQ175) background. Mice were genotyped using primers
specific for human HTT, and age-matched WT littermates were used as controls for all
experiments. All experiments were performed with male mice exclusively. Animals were housed
in enriched, temperature-controlled environments with a 12-hour light/dark cycle. Food and water
were provided ad libitum.
Western Blots
Hearts were homogenized by beat mill (Qiagen) for 5 minutes at 50 Hz with a 5 mm
stainless steel bead in 250 ml TBS disruption buffer containing 50 mM Tris (pH 8.0), 150 mM
NaCl, Complete protease inhibitors (Roche), and Phos-STOP phosphatase inhibitors (Roche).
Following disruption, 750 ml protein extraction buffer was added to samples containing 50 mM
Tris (pH 8.0), 150 mM NaCl, 1.333% Triton-X, 0.1333% SDS, 0.667% sodium deoxycholate,
complete protease inhibitors, and Phos-STOP phosphatase inhibitors. (Combination of disruption
and extraction buffers in a 250 µl:750 µl ratio yields 1X RIPA buffer containing 50 mM Tris (pH
8.0), 150 mM NaCl, 1% Triton-X, 0.1% SDS, 0.5% sodium deoxycholate, and
protease/phosphatase inhibitors.) Samples were allowed to incubate for 1 hour at 4°C with
agitation before clarifying by centrifuging at 16,000 x g for 15 minutes. Total protein concentration
was determined by BCA (Pierce). 30 µg of protein was reduced and separated by SDS-PAGE on
12% bis-tris polyacrylamide gels in MOPS buffer (Bio-Rad), then transferred to 0.2 µm PVDF
(Bio-Rad). Antibodies used are described in Table 2. Blots were developed using ECL Plus
Western Blotting Detection System (GE Healthcare) and imaged digitally on a ChemiDoc MP
imaging system (Bio-Rad). Blots were stripped no more than two times using Restore Stripping
Buffer (Thermo) for 9 minutes at 37°C. Densitometry was performed using NIH ImageJ software.
Densities of bands detected by phospho-antibodies were normalized to densities of bands
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detected by phospho-independent antibodies in same lane. Phospho-independent antibody
densities were normalized to αTubulin or Na/K-ATPase band in same lane.
Immunohistochemistry
Excised hearts were bisected transversely and the apical sections post-fixed in 4% PFA
for at least 24 hours. Samples were dehydrated and processed by the CHOP Pathology Core. 5-7
µm sections were cut from paraffin blocks on a rotary microtome (Microm), mounted, then heated
at 55°-60° to remove excess paraffin and cement sections. Sections were then rehydrated
through xylene and ethanol, followed by heat-induced epitope retrieval for 3 minutes using a
pressure cooker and sodium citrate buffer (10 mM Sodium citrate, 0.05% Tween 20, pH 6). Slides
were washed in TBS with 0.025% Triton-X, termed here TBS-TX, and then blocked in 10%
normal serum with 1% BSA in TBS at RT for 2 hours. Primary antibody P-S6 (Cell Signaling,
4858, 1:200) was diluted in 1% BSA in TBS-T and incubated on tissue samples overnight at 4°C.
Sections were washed in TBS-TX and blocked in 0.3% H2O2 the next day. For detection, sections
were incubated with a biotin-conjugated secondary antibody for 1 hour at RT, followed by
incubation in ABC solution for 30 min at RT to amplify signal. Sections were developed using
DAB and H2O2 until color was visible, about 90 seconds.
After IHC development, slides were counterstained in Harris hematoxylin for 2 minutes.
Stained sections were rinsed in tap water, destained by two dips in a solution of 70% ethanol and
0.25% HCl, then allowed to blue by rinsing in running tap water for 2 minutes. Sections were then
dehydrated through ethanol, cleared in xylene, and mounted with DPX.
In situ GFP fluorescence microscopy
Tissues from saline-perfused mice were excised and post-fixed in 4% PFA overnight.
They were cryoprotected in a solution of 30% sucrose, 0.1 M Tris HCl (pH 7.0), 0.05% NaN 3 until
tissues sank, then moved to liquid OCT. For embedding, tissue molds were placed in a 2methylbutane bath so that the 2-methylbutane was over the level of the OCT within the mold but
not over the top of the mold itself. The system was then placed in liquid nitrogen until the OCT
solidified. 10 µm tissue sections were cut on a cryostat and sections were allowed to melt onto a
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SuperFrost Plus slide (Fisher) at RT. Slides were briefly washed 2X in PBS to remove excess
OCT, mounted with Fluorogel, and imaged on a Leica DM6000B light microscope.
Viral preparation and gene transduction
Cardiotropic AAV (termed CT.AAV) was developed by inserting a novel nine-residue
peptide sequence identified by Yonghong Chen through phage panning into the cap gene of
AAV2. Genes of interest were cloned into a standard AAV2 expression cassette. MicroRNA
systems (mi2.1, miCTRL) were previously developed by the lab (134) and were driven by a U6
promoter. mHTT overexpression systems (eGFP, N171-12Q, and N171-82Q) were made by
cloning the gene of interest—available on plasmids previously developed by the lab—
downstream of the chicken troponin T (cTnT) promoter. The cTnT promoter has been shown to
be an effective means of cardiac gene overexpression using AAV transduction (153, 154) and
was ordered as a custom G-block with unique 5’ and 3’ restriction sites from IDT. All AAVs were
produced by the Research Vector Core at The Children’s Hospital of Philadelphia. Titers
(measured in viral genomes/ml) were determined by qPCR.
For vector delivery, mice were injected with 7.5e10 viral genomes (vg)/g body mass via
jugular vein injection (JVI) following a validated protocol (155). JVI was selected over tail vein
injection because of the proximity to the target tissue (heart), and because the relatively large
size helps minimize loss of valuable vector to technical errors. Briefly, mice were anesthetized
with isoflurane and placed in the supine position. The skin directly over the right clavicle was
shaved and cleaned, and a small, superficial incision was made at the approximate midclavicular
line. The superior insertion point of the right pectoralis muscle was identified and the internal
jugular vein isolated. The injection was made with an insulin syringe by advancing the needle
through the pectoralis muscle into the jugular vein. The pectoralis muscle served to both stabilize
the needle and provide pressure on the vein once the needle was removed. The wound was
closed by either continuous stitching or wound clips, with wound clips removed 7-10 days after
surgery.
Quantitative PCR
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For in-depth explanation of qPCR protocol, see Chapter 2: Materials and Methods.
Briefly, RNA was extracted from snap-frozen mouse hearts using Trizol (Ambion). cDNA libraries
were constructed from 2 µg RNA template using with random hexamer primers and a High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). SYBR Green qPCR was
performed using either custom-designed primer sets, or pre-designed and validated primer sets
purchased from IDT. Genes that utilized pre-designed primers sets in this chapter include: HTT,
FoxO1, Bnip3, and Igf1r. For custom-designed primer sets used in this chapter, see Table 3.
Data was analyzed using either the 2-ΔΔCt method, or by creating a standard curve from known
concentrations of plasmid DNA each containing a single copy of the gene of interest.
BCAA Injections
N171-82Q and WT mice were daily 2 ml injections of a branched chain amino acid
cocktail containing 6 mg/ml L-isoleucine, 12 mg/ml L-leucine, 7.2 mg/ml L-valine, and 6.04 mg/ml
L-arginine. Injections were started at 10 weeks of age and continued until 16 weeks of age. At
experiment endpoint, hearts were excised and snap frozen for WB analysis.
Membrane Extraction
Membrane fractions were extracted from snap-frozen heart tissue using a MEM-Per Plus
kit (Thermo) according to manufacturer’s protocol. Preliminary extraction protocols employing
Triton-X114 used a bead mill for homogenization and found that all proteins separated with the
cytoplasmic fraction, thus demonstrating the importance of a more sensitive homogenization
protocol. For experiments here, tissue was homogenized in the appropriate buffer using a
Dounce homogenizer, 5 strokes with pestle A (coarse) and 3 strokes with pestle B (fine).
Statistical Analyses
All data was analyzed either by Student’s T-test or one-way ANOVA with Tukey’s posthoc analysis, with p ≤ 0.05 considered significant for all tests. Statistics were performed in
GraphPad Prism version 7.
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Table 2: Antibodies used for Chapter 3
Company
Cell Signaling

AbCam
Santa Cruz
Sigma
GE Healthcare

Antigen
P-S6 (ser235/236)
S6
P-4EBP1 (ser65)
4EBP1
P-Akt (ser473)
Akt
P-mTOR (ser2448)
mTOR
P-AMPKα (thr172)
P-p44/42 MAPK
(thr202/tyr204)
p44/42 MAPK
Rheb
Na/K-ATPase
HTT
AMPKα
αTubulin
Anti-mouse HRP
Anti-rabbit HRP
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Product ID
4858
2217
9451
9644
4060
4691
5536
2983
2535
4370

WB Dilution
1:1000
1:1000
1:500
1:1000
1:500
1:1000
1:500
1:1000
1:1000
1:1000

4695
13879
ab76020
ab109115
sc-25792
T5168
NA931
NA934

1:1000
1:1000
1:100,000
1:5000
1:1000
1:2000
1:20,000
1:15,000

Table 3: Custom-designed primers for Chapter 3
Gene Name

Forward Primer

Reverse Primer

FoxO3

GGCAAAGCAGACCCTCAAAC

TGGGAGTCTCAAAGGTGTCAAG

GFP

AAGGGCATCGACTTCAAGG

TGCTTGTCGGCCATGATATAG

Tbp

TACCGTGAATCTTGGCTGTAAAC

GTTGTCCGTGGCTCTCTTATTC
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Figure 18: mTORC1 activity is decreased in HD mouse hearts.
(A) Representative western blot analysis for P-S6 and P-4EBP1 in hearts of N171-82Q
mice and WT littermates at 6 (n ≥ 6), 10 (n ≥ 7), 14 (n ≥ 8), and 18 (n ≥ 8) weeks of age, and in
zQ175 mice and WT littermates at 12 months of age (n ≥ 10). Total (phospho-independent) S6
and 4EBP1 serve as references. Blots were quantitated by densitometry analysis to determine
(B) P-S6 levels and (C) P-4EBP1 levels in HD mouse hearts relative to WT. Phosphoprotein band
densities were normalized to total protein band densities from the same lane. Data shows
decreased P-S6 and P-4EBP1 in HD hearts in both genotypes and at all time points. Error bars
represent SEM. Student’s t-test, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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Figure 19: P-S6 immunostaining shows decreased mTORC1 activity in HD mouse hearts.
Immunostaining of heart sections from N171-82Q and WT mice at 6 (n ≥ 5) and 14 weeks
of age (n ≥ 10), and from zQ175 and WT mice at 12 months of age (n ≥ 10). P-S6 in heart tissue
seems to stain positive at intercalated discs between adjacent cardiomyocytes. In HD mouse
hearts, P-S6 stains less dense than in WT hearts, confirming western blot data and suggesting
decreased mTORC1 activity. Scale bars = 20 µm.
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Figure 20: CT.AAV preferentially transduces cardiomyocytes.
Biodistribution analysis of systemically-injected CT.AAV delivering a GFP transgene (n =
4). Saline-injected animals were used as controls (n = 4), and images here represent in situ GFP
fluorescence. Sections displayed were taken from heart, liver, and skeletal muscle. AAV typically
transduces liver at much higher magnitude than the heart, but here ventricle and atria are clearly
show much more fluorescence than either liver or skeletal muscle. Liver does have a small
amount of expression relative to saline controls. Skeletal muscle exhibits considerable
autofluorescence, and there is no distinguishable difference between saline and CT.AAV-injected
samples.
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Figure 21: CT.AAV.mi2.1 injection knocks down mHTT in N171-82Q mouse hearts.
Confirmation of mHTT KD in N171-82Q mouse hearts from animals injected with either
formulation buffer (FB, n = 8), CT.AAV.miCTRL (n = 8), or CT.AAV.mi2.1 (n = 7). (A) Quantitative
PCR to determine expression of mHTT mRNA in N171-82Q KD mouse hearts and controls.
Analysis shows a 40% knock-down in mice from CT.AAV.mi2.1-injected mice relative to FBinjected controls. Tbp was used as an internal control for each sample. (B) Representative WB for
HTT protein in N171-82Q KD mouse hearts and controls. Bands displayed represent transgenic
N171-82Q fragment, which runs at approximately 44 kD. (C) Densitometry analysis of HTT WB to
confirm mHTT at the protein level. Data were normalized to αTubulin band densities from the
same lane and graphed relative to FB-injected controls. Results demonstrate a 35% KD of the
mHTT transgenic fragment in CT.AAV.mi2.1-injected HD mice relative to FB-injected controls.
Error bars represent SEM. One-way ANOVA with Tukey’s post-hoc analysis, *p ≤ 0.05, **p ≤
0.01.
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Figure 22: mHTT knock down in N171-82Q mouse hearts restores mTORC1 activity.
Analysis of mTORC1 activity in N171-82Q mouse hearts injected with either formulation
buffer (FB, n = 8), CT.AAV.miCTRL (n = 8), or CT.AAV.mi2.1 (n = 7). (A) Representative WB for
P-S6 and P-4EBP1 in N171-82Q mouse hearts with mHTT KD (mi2.1) or controls. Densitometry
analysis was performed to quantitate (B) P-S6 levels and (C) P-4EBP1 levels. Phosphoprotein
band densities were normalized to total protein band densities in the same lane. Data were
graphed relative to FB and show significantly increased mTORC1 activity in hearts from N17182Q mice injected with CT.AAV.mi2.1 relative to controls, suggesting mHTT expression is
necessary for mTORC1 dysregulation. Error bars represent SEM. One way ANOVA with Tukey’s
post-hoc analysis, *p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.
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Figure 23: Confirmation of transduction in WT mice overexpressing mHTT.
Quantitative PCR to confirm gene transduction in hearts of WT mice injected with
formulation buffer (FB, n = 8), CT.AAV.eGFP (n = 8), CT.AAV.N171-12Q (n = 9), or
CT.AAV.N171-82Q (n = 8). Genes analyzed were (A) eGFP and (B) human HTT. Standard
curves were generated for each gene and data therefore represent copy numbers/ng RNA.
Primers for human HTT do not differentiate between 12Q and 82Q variants, but do not amplify
endogenous mouse HTT. While successful HTT expression is demonstrated, the levels are only
20% of that in N171-82Q hearts (data not shown).
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Figure 24: mHTT overexpression in WT hearts does not impair mTORC1 activity.
(A) Representative WB of mTORC1 activity indicators P-S6 and P-4EBP1 in WT hearts
injected with either FB (n = 8), CT.AAV.GFP (n = 8), CT.AAV.N171-12Q (n = 9), or
CT.AAV.N171-82Q (n = 8). Bands shown are from non-adjacent lanes on the same blot.
Densitometry analysis was used to quantitate levels of (B) P-S6 and (C) P-4EBP1 normalized to
phospho-independent band densities from the same lane. No differences in mTORC1 activity
were observed between transduced gene, suggesting that mHTT expression may not be
sufficient for mTORC1 dysregulation, but these results may also result from relatively low levels
of mHTT expression. Error bars represent SEM.
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Figure 25: mTORC1 activation cascade.
Simplified schematic of mTORC1 activation pathway from extracellular signals to
mTORC1 phosphorylation of S6 and 4EBP1. Arrows represent activation steps, blunted lines
represent inhibition steps. Notably not pictured are subcellular localization requirements.
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Figure 26: Extracellular signals do not contribute to mTORC1 dysregulation in HD mouse
hearts.
(A) ELISA analysis of serum IGF-1 from N171-82Q mice and WT littermates at 6 (n ≥ 5)
and 14 weeks of age (n ≥ 7) and from zQ175 mice at 6 (n ≥ 5) and 12 months of age (n ≥ 12).
Data are graphed relative to WT for each time point. Surprisingly, IGF-1 was increased in 6 weekold N171-82Q mice despite decreased mTORC1 activity. (B) ELISA measurement of serum
insulin from N171-82Q and zQ175 mice at similar time points as panel (A). Note that while serum
insulin is decreased in 14 week-old N171-82Q mice, serum was collected during the day, at an
age where daytime feeding is significantly decreased (Figure 12). (C) Quantitative PCR analysis
of IGF-1 receptor gene expression (Igf1r) in HD mouse hearts relative to age-matched WT
littermates at 6 (n ≥ 6), 10 (n ≥ 7), 14 (n ≥ 8), and 18 (n ≥ 8) weeks of age for N171-82Q mice,
and 12 months of age (n ≥ 10) for zQ175 mice. Tbp expression was used as an internal control.
Data are graphed relative to WT for each time point. Interestingly, Igf1r expression increases in
N17-82Q mice with age, suggesting a possible compensatory role. Error bars represent SEM.
Student’s T-test, *p ≤ 0.05, **p ≤ 0.01.
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Figure 27: Erk activation is not impaired in HD mice.
(A) Representative western blot analysis of phospho-Erk1 and phospho-Erk2 in N17182Q and WT mouse hearts at 6 weeks (n ≥ 6), 10 weeks ( n ≥ 10), 14 weeks (n ≥ 8), and 18
weeks (n ≥ 8) of age, and in zQ175 and WT mouse hearts at 12 months (n ≥ 6) of age.
Densitometry quantitation of (B) P-Erk1 and (C) P-Erk2 levels showed no difference in
phosphorylated protein levels between WT and HD in either line or at any time point, suggesting
no impairment of IGF-1 signaling. Band densities of phosphoproteins were normalized to
phospho-independent band densities from the same lane. Data are plotted relative to WT. Error
bars represent SEM. Student’s T-test (no significant differences).
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Figure 28: Expression of Pten does not explain mTORC1 dysregulation in HD mouse
hearts.
Quantitative PCR to determine Pten expression in N171-82Q at WT mice 6 (n ≥ 6), 10 (n
≥ 7), 14 (n ≥ 8), and 18 (n ≥ 8) weeks of age, and in zQ175 and WT mice at 12 months of age (n
≥ 10). Expression of Tbp was used as an internal control and data were graphed relative to WT
levels. Pten expression was mildly but significantly increased at 6 weeks in N171-82Q mice,
decreased at 10 weeks, and normal at later time points and in zQ175 mice. Thus, it is highly
unlikely that it is affecting mTORC1 activity. Error bars represent SEM. Student’s T-test, *p ≤
0.05.
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Figure 29: Diminished upstream pathway activation may explain mTORC1 dysregulation in
early-stage HD mice.
(A) Representative WB and quantitation to assess levels of (B) phospho-Akt (P-Akt) and
(C) phospho-mTOR (p-mTOR) in N171-82Q mice at 6 (n ≥ 6), 10 (n ≥ 7), 14 (n ≥ 8), and 18 (n ≥
8) weeks of age, and in zQ175 mice at 12 months of age (n ≥ 10). Age-matched WT littermates
were used as controls. Protein levels were quantitated by densitometry analysis, normalizing
band densities of phosphoproteins to band densities of the same phospho-independent protein.
Decreased levels of P-Akt and P-mTOR in 6 week-old N171-82Q and 12 month-old zQ175 mice
relative to WT suggests decreased axis activation, explaining the dysregulated mTORC1 at these
time points. However, in post-symptomatic N171-82Q mice the axis activation normalizes but
mTORC1 activity is still dysregulated, suggesting a distinct etiology in later disease stages. Error
bars represent SEM. Students T-test, *p ≤ 0.05, **p ≤ 0.01.
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Figure 30: AMPK is not activated in HD mouse hearts.
(A) Representative WB and (B) densitometry quantitation for activated (phosphorylated)
AMPK in N171-82Q mice at 6 (n ≥ 6), 10 (n ≥ 7), 14 (n ≥ 8), and 18 (n ≥ 8) weeks of age, and in
zQ175 mice at 12 months of age (n ≥ 10). Age-matched WT littermates were used as controls.
Phosphoprotein band densities were normalized to phospho-independent protein band densities
and graphed relative to WT. No differences were observed, suggesting that AMPK is not
activated in N171-82Q or zQ175 hearts at the time points tested and therefore does not explain
mTORC1 dysregulation. Error bars represent SEM. Student’s T-test.
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Figure 31: Expression of FoxO1 and FoxO3 are increased in HD but may not contribute to
mTORC1 dysregulation.
Quantitative PCR analyses to determine expression levels of FoxO-family transcription
factors and downstream product Bnip3, an mTORC1 inhibitor, in N171-82Q hearts at 6 (n ≥ 6), 10
(n ≥ 7), 14 (n ≥ 8), and 18 (n ≥ 8) weeks of age, and in zQ175 mice at 12 months of age (n ≥ 10).
Levels of (A) FoxO1 are increased at all time points in N171-82Q mice and in zQ175 mice relative
to WT. Additionally, levels of (B) FoxO3 are increased at 14 and 18 weeks in N171-82Q mice.
However, while significant, the increases are relatively mild, and expression of (C) Bnip3 is not
different from WT at any time point in either mouse line. Thus, while the FoxO transcription
factors may be mildly upregulated in HD mouse hearts, it is unlikely that they are having an effect
on mTORC1. All genes used Tbp as an internal control and are graphed relative to WT. Error
bars represent SEM. Student’s T-test, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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Figure 32: BCAA injection does not restore mTORC1 activity in N171-82Q mice.
(A) Representative western blot and densitometry analysis of (B) P-S6 and (C) P-4EBP1
levels in hearts from N171-82Q and WT mice injected daily with branched chain amino acid
(BCAA) cocktail starting at 10 weeks of age and continuing until 16 weeks of age. For each
group, n ≥ 6. Phosphoprotein band densities were normalized to phospho-independent band
densities for the same protein in the same lane. Results show that BCAA injections did not
significantly increase mTORC1 activity mouse hearts of either genotype. Error bars represent
SEM. One-way ANOVA with Tukey’s post-hoc analysis.
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Figure 33: Rheb is mislocalized in late-stage N171-82Q mouse hearts.
Membrane extraction of 16 week-old (late-stage disease) N171-82Q and WT mouse
hearts (n = 6/genotype), followed by WB for Rheb, shows preferential Rheb localization in the
cytoplasmic fraction rather than the membrane fraction. (A) Representative WB and (B)
densitometry quantitation normalizing to Na/K-ATPase for membrane fraction and αTubulin for
cytoplasmic fraction. Error bars represent SEM. Student’s T-test, ***p ≤ 0.001.
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Figure 34: Rheb localization is not altered in 6 week-old N171-82Q mouse hearts.
(A) Representative WB for Rheb and (B) densitometry quantitation of membrane and
cytoplasmic fractions from 6 week-old N171-82Q and WT hearts. Na/K-ATPase was used as a
control for membrane factions and αTubulin was used as a control for cytoplasmic fractions.
While total cytoplasmic Rheb was moderately but significantly decreased in HD cytoplasmic
fractions relative to WT, there was no difference in membrane-associating Rheb between HD and
WT. Thus, it is unlikely that Rheb mislocalization contributes to mTORC1 dysregulation in
presymptomatic N171-82Q hearts. Error bars represent SEM. Student’s T-test, *p ≤ 0.05.
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Figure 35: Rheb localization is not affected in 12 month-old zQ175 hearts.
Representative WB for Rheb in cytoplasmic and membrane fractions from 12 month-old
zQ175 and WT hearts (n = 6/genotype). Bands were not quantitated due to absence of Rheb
signal in membrane fractions from both genotypes. Na/K-ATPase and αTubulin were used as
loading controls for membrane and cytoplasmic fractions, respectively. The absence of
membrane-localized Rheb in either WT or HD suggests Rheb mislocalization is likely not
contributing to mTORC1 dysregulation in these hearts.
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CHAPTER 4: FUNCTIONAL CONSEQUENCES OF CARDIAC MTORC1
DYSREGULATION HD MICE
Introduction
Decreased mTORC1 activity in HD mouse hearts can lead to multiple downstream
consequences. Cardiac mTORC1 activity is essential for development (119), but it seems to be
less critical in healthy adult hearts. For instance, the mTORC1-specific inhibitor everolimus is
commonly used for its immunosuppressive properties in heart transplant patients and has
excellent outcomes (156), demonstrating that mTORC1 suppression is well tolerated even in
some of the most fragile hearts. That is not to say, however, that mTORC1 has no function in
adult hearts: cardiac-specific mTor knockout in adult mice quickly leads to dilated cardiomyopathy
and death (121). Partially suppressing its activity, though, seems to be well-tolerated in healthy
hearts. Where mTORC1 activity becomes more obligatory is in mediating the cardiac
hypertrophic response to stress.
Cardiac stress occurs when the heart must increase its work to supply the body’s oxygen
needs. Many different physiologic and pathophysiologic mechanisms can induce cardiac stress,
including endurance and strength training (157), ischemic heart injury, systemic hypertension,
valve abnormalities, arteriovenous fistulae, etc. (158). Typically, the heart responds by
hypertrophy, an adaptive mechanism that decreases the amount of work each individual
sarcomere must exert while maintaining a sufficient cardiac output (159). Since cardiomyocytes
are non-dividing cells, hypertrophy occurs by increasing sarcomere size and structure within the
existing cardiomyocyte; pressure overload causes addition of new sarcomeres in parallel and
leads to thickened ventricles, whereas volume overload stimulates addition of new sarcomeres in
series and leads to ventricular dilatation (160). Though heart hypertrophy is initially adaptive, left
unchecked it becomes pathologic. Eventually ventricular efficiency and compliance decrease,
coronary blood flow can become impinged by the thickened myocardium, and heart failure
ensues (82). These maladaptive changes are common end stages of many forms of heart
disease, so heart hypertrophy studies generally focus on how to delay or stop it. However, in its
adaptive capacity, hypertrophy provides a role essential to survival.
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The adaptive or physiologic phase of heart hypertrophy is mediated by mTORC1.
Comparison of physiologic and pathologic hypertrophy in mice found cardiac mTORC1 activity
was increased in exercised mice, but decreased in end-stage pressure-overloaded animals (161).
These observations imply that, with a chronic stressor, the initial adaptive changes are mediated
by mTORC1, but later maladaptive or pathologic hypertrophy occurs via an mTORC1independent mechanism. Accordingly, cardiac-specific mTor knockout mice rapidly developed
dilated cardiomyopathy with increased apoptosis, fibrosis, and complete lack of hypertrophy in
response to stress. (121). Conversely, overexpression of mTOR attenuated pressure overloadinduced fibrosis and reduced inflammatory cytokine responses (162). While these phenotypes
demonstrate the importance of mTOR function in the heart, they necessarily affect mTORC2
activity, a second mTOR-based complex that promotes cell survival and polarity. A more specific
mTORC1 ablation was accomplished with cardiac-specific raptor deletion (a defining mTORC1
subunit), which caused maladaptive responses to pressure overload resulting in dilated
cardiomyopathy and heart failure (123). Together, these results suggest that the adaptive stress
response is simply bypassed in the absence of mTORC1, with stress inducing immediate onset of
pathologic heart hypertrophy and increased mortality.
While cardiac mTORC1 suppression by small-molecule inhibitors is well-tolerated in the
absence of heart disease, stressed hearts may be much more sensitive to changes in mTORC1
levels. Rapamycin, a small molecule mTORC1 inhibitor, prevented cardiac compensation and led
to increased mortality in volume and pressure overload mouse models (122, 163). Thus, stressed
hearts have a marked reliance on mTORC1 activity for the physiologic adaptation phase. It is
thus likely that the mTORC1 dysregulation I observed in HD mouse models underlies the
previously described inability to hypertrophy (87) and the increased fibrosis (85) in response to
stress. To test this hypothesis, I first validated the stress response phenotype in HD mice, then
restored mTORC1 activity by gene therapy techniques to observe how it changed the phenotype.
Results
HD mouse hearts do not adapt to cardiac stress
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In order to induce stress in HD mouse hearts I used continuous isoprenaline (ISO)
infusion, a non-specific β-adrenergic agonist that binds β-adrenergic receptors with more affinity
than epinephrine or norepinephrine. ISO treatment is frequently used as a cardiac stress model in
rodents and mimics adrenergic conditions associated with pressure overload (164). Because
previous cardiac stress studies in HD animals utilized the R6/2 and BACHD models, I first
confirmed and further characterized the phenotypes in N171-82Q mice. The most apparent
response after starting ISO infusions was significantly increased mortality. ISO-treated N171-82Q
mice at 12 weeks of age experienced 50% mortality over the course of the 14 day study,
compared to 15% among saline-treated HD mice and 0% among both of the WT groups (Figure
36). I repeated the experiment in 18 month-old zQ175 mice, expecting to see a lower rate of
mortality than with the N171-82Q line because of the generally more subtle and slowerprogressing phenotypes. To the contrary, aged zQ175 mice experienced a rapid 83% mortality,
compared to 25% among the stressed WT mice and 0% in both of the saline treated groups
(Figure 37). This augmented ISO-related mortality in both genotypes relative to saline-treated
controls suggests that increased age contributes to pathogenesis, and combined with mHTT
expression produces robust results. Interestingly, mortality in both studies started almost
immediately but soon plateaued, with a subset of the stressed HD animals (50% in N171-82Q
mice and 17% in zQ175) surviving the entire 14 days (Figures 36-37). Thus, the surviving HD
mice may have been able to achieve some level of adaptation. Nevertheless, the increased
mortality in both genotypes suggest that, in general, HD mice have limited compensation to
cardiac stress.
I explored the in vivo stress response in HD mice using transthoracic echocardiography. I
obtained imaging data in HD and WT mice at baseline, prior to ISO (or treatment control) delivery,
and again 5 and 12 days later, and assessed the temporal change from baseline. ISO-stressed
N171-82Q mice had increased fractional shortening (FS), heart rate (HR), cardiac output (CO),
and ejection fraction (EF) at trial days 5 and 12 relative to baseline, but there was no significant
change in left ventricular mass (LV mass) (Figure 38A-C, F-G). Conversely, ISO-stressed WT
animals showed significant LV mass increase from baseline at trial days 5 and 12, with
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unchanged or no significant changes in FS, HR, CO, and EF at both time points (Figure 38A-C,
F-G). ISO did not induce measurable changes in LVEDV or LVESV in either genotype (Figure
38D-E). These results demonstrate that WT hearts employ a hypertrophic adaptation in response
to chronic ISO stress, whereas HD hearts undergo sustained increase of heart rate and
contractility but do not hypertrophy.
To confirm limited hypertrophy as measured by echocardiography, I measured both gross
heart mass and cardiomyocyte cross-sectional area post necropsy and tissue sectioning.
Average heart mass/tibia length increased by 35.3% in WT animals treated with ISO relative to
saline-treated WT controls and by a blunted 18.7% in HD animals treated with ISO relative to
saline-treated HD controls (Figure 39). While I was not expecting to see any evidence of mass
increase in hearts from stressed HD mice based on previous reports (87), this data reflects only
the mice surviving to trial endpoint and therefore includes a survivor bias. Additionally, multiple
factors besides hypertrophy can contribute to increased gross heart mass, so I examined
cardiomyocyte cross-sectional area as a more sensitive measurement of heart hypertrophy. ISO
induced robust cardiomyocyte cross-sectional area increase in WT mice relative to saline-treated
controls, but it failed to increase the cross-sectional area of HD cardiomyocytes (Figure 40), thus
confirming absence of a hypertrophic response in HD mouse hearts.
Maladaptive cardiac changes are associated with fibrosis and cardiomyocyte death. I
therefore stained heart sections with picrosirius red (Figure 41A-B) and Masson’s Trichrome
(Figure 41C), and found that both WT and HD mice treated with ISO had increased fibrosis
relative to saline treated animals, but the extent of fibrosis was significantly greater in HD hearts
(Figure 41D). As fibrosis is compensatory to cardiomyocyte death, I next queried expression of
genes encoding the apoptosis activator Bax and the anti-apoptotic factor Bcl2. Bax was
moderately but significantly elevated in ISO-treated HD and WT hearts relative to saline controls
and Bcl2 expression was decreased in stressed hearts, indicating that ISO stress promotes
apoptosis in hearts from both genotypes (Figure 42). However, the differences in fibrosis infer
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that stressed WT hearts likely have activated other anti-apoptotic activators, as pathologic
changes are clearly less severe than in stressed HD animals.
Decompensated heart failure occurs when maladaptive processes begin to impair cardiac
function, which leads to increased pulmonary pressure and subsequent fluid accumulation in the
lungs. The wet/dry lung mass ratio can therefore be used as an indicator of heart failure.
Examination of the lungs from N171-82Q and WT mice treated with ISO or saline for 14 days
showed no differences in wet/dry ratio between any group, suggesting that decompensated heart
failure is not associated with any genotype-treatment combination at this time point (Figure 43).
However, only lungs from animals that survived to the end of the trial were included in the
analysis due to rapid, confounding, post-mortem lung changes.
Given mTORC1’s role in adaptive hypertrophy, I measured mTORC1 indicators in the
stressed hearts from both WT and HD animals that survived to trial endpoint. Interestingly, PS6/S6 levels were increased in ISO-stressed hearts from both genotypes, with notable variance
in HD hearts (Figure 44A-B). P-4EBP1/4EBP1 levels were not different among treatment groups,
but had a similar large variability observed in surviving stressed HD mice hearts (Figure 44A, C).
These observations infer that partially overcoming the inherent cardiac mTORC1 dysregulation in
HD mice may allow some adaptation and be associated with survival.
Restoration of mTORC1 activity in HD hearts rescues stress adaptation
The cardiac stress response in N171-82Q mice resembles that observed in other HD
mouse models (85, 87), and is also similar to that of mTORC1-inhibited mice (121-123). I thus
studied the relevance of mTORC1 inhibition in N171-82Q mouse hearts by selectively activating
cardiac mTORC1. I utilized CT.AAV to express a constitutively active variant of Rheb (RhebS16H, or simply caRheb) or GFP in HD mice hearts (165), and I confirmed transduction by
western blot (Figure 45). Two weeks after vector delivery, I started ISO or saline infusion to
induce heart stress as before. As expected, HD mice injected with CT.AAV.GFP and treated with
ISO (GFP-ISO) experienced 40% mortality relative to saline-treated mice transduced with
CT.AAV. GFP (GFP-saline) (Figure 46). In contrast, HD mice transduced with CT.AAV.caRheb
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and treated with either isoprenaline or saline (caRheb-ISO and caRheb-saline, respectively)
displayed only 5% mortality over the course of the study (Figure 46). Mortality rates among the
HD mice in this experiment and the previous one are similar but not identical, and they are likely
due to variation in overall cohort-to-cohort health. Despite the differences, this experiment shows
that cardiac caRheb expression ameliorates sensitivity to ISO stress in HD mice.
In addition to the decreased mortality, CT.AAV.caRheb injection restored functional
elements of the cardiac stress response in HD mice on transthoracic echocardiogram. Imaging
showed that mice in the GFP-ISO group had increased FS, HR, and EF from baseline without an
increase in LV mass at trial days 5 and 12 (Figure 47A-C, G), similar to the observations made in
stressed non-AAV-treated N171-82Q mice (Figure 38). Conversely, mice in the caRheb-ISO
group responded to stress with an increase in LV size from pretreatment levels, with no changes
in FS, HR, or EF from pretreatment levels at either time point (Figure 47A-C, G), approximating
the WT response to chronic ISO (Figure 38). There were no measurable changes in LVEDV,
LVESV, and CO for either vector (Figure 47D-F). These measurements collectively imply that
caRheb transduction restores the functional elements of the adaptive stress response in HD
hearts.
I studied the effects of caRheb transduction on heart hypertrophy by examining heart
mass/tibia length. There were no differences observed between mouse hearts from the GFPsaline, GFP-ISO, and caRheb-saline groups. However, caRheb-ISO treated HD mice
experienced a 27.5% increase in heart mass/tibia length (Figure 48), implying mTORC1
activation successfully permitted heart hypertrophy in response to stress. This conclusion was
confirmed by analysis of cardiomyocyte cross-sectional area, which showed that mice in the
caRheb-ISO group experienced robust cross-sectional area increase relative to all other groups,
representing restored hypertrophic adaptation (Figure 49). As predicted, there was no difference
in cardiomyocyte mean cross-sectional area between the GFP-saline and GFP-ISO groups
(Figure 49). Mice in the caRheb-saline group had moderately increased cardiomyocyte crosssectional area relative to the GFP-saline group, an expected finding given mTORC1’s role in
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promoting growth, but probably too subtle to be observed on echocardiography (Figure 49).
These analyses clearly indicate that restoring cardiac mTORC1 activity in HD mice permits
adaptive heart hypertrophy with ISO stress.
The impact of caRheb on restoring adaptive hypertrophy and preventing stress-related
pathologic changes in N171-82Q hearts was apparent in analyses of fibrosis by picrosirius red
(Figure 50A-B) and Masson’s trichrome stains (Figure 50C). Extensive fibrosis was present in
HD mouse hearts from the GFP-ISO group, whereas fibrosis in hearts from the caRheb-ISO
group was comparatively mild (Figure 50D). Thus, caRheb expression successfully decreases
pathological changes in N171-82Q hearts. Interestingly, qPCR analysis of apoptotic factors
showed moderately but significantly increased Bax expression in hearts from the caRheb-ISO
group only, and no significant changes in Bcl2 expression (Figure 51), though considering the
differences in fibrosis this probably reflects a survivor bias more than it does ongoing apoptosis.
Similar to before, wet/dry lung mass ratios of mice surviving to trial endpoint were not
different between groups, suggesting that the mice included in the analysis were not experiencing
decompensated heart failure at the time of observation (Figure 52). Additionally, as before,
mTORC1 activity in hearts of surviving animals was increased with ISO treatment (Figure 53AC). While P-S6/S6 levels in caRheb-transduced mice groups trended higher than their respective
GFP-transduced mice groups, they did not achieve statistical significance due in part to large
variance in GFP-ISO samples (Figure 53B). These results thus support the hypothesis that the
ability to overcome dysregulated cardiac mTORC1 activity in HD hearts, through endogenous or
exogenous means, is associated with survival in response to stress.
HD mouse hearts have impaired autophagy and mitochondrial biogenesis
Cardiac mTORC1 dysregulation in HD mouse hearts clearly impairs adaptation to stress
and may therefore explain heart disease-related mortality in HD patients. mTORC1, though,
regulates many different molecular pathways, and they may not all contribute equally to stress
sensitivity in HD mice. Deletion of cardiac mTor in adult mice had a severe and fatal phenotype
but was largely rescued with 4ebp1 deletion, suggesting that global protein synthesis is the
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critical molecular mechanism in the adaptive stress response (121). Alternatively, HD mouse
hearts had decreased ATP and a shift away from oxidative metabolism, suggesting that
mitochondrial function may be the key inhibitory condition (91). Understanding which downstream
mechanisms contribute most to the impaired stress response could help guide future therapeutic
strategies in a manner that limits adverse effects.
In order to better understand the molecular consequences of mTORC1 dysregulation in
HD hearts, I made preliminary studies of two cellular mechanisms regulated by mTORC1,
autophagy and mitochondrial biogenesis. Autophagy, is a cellular process to dispose of and
recycle old, improperly folded, or nonfunctional cellular machinery (166) and is canonically
inhibited by mTORC1. Consequently, small molecule mTORC1 inhibitors are frequently used as a
means of promoting autophagy for experimental purposes (167, 168). Despite dysregulated
mTORC1 activity in the brain, HD is associated with decreased autophagy (130). In order to
examine autophagy in HD mouse hearts I measured post-translational modification of LC3, a
component of autophagic vesicles that is cleaved from its pro-form to LC3-I, then lipidated to the
mature LC3-II. Previous work has shown that LC3-II levels correlate with the number of
autophagic vesicles within a cell, and LC3-II therefore serves as a crude indicator of autophagy
(169). In N171-82Q mouse hearts, LC3-II was increased at 6 weeks of age, consistent with
decreased mTORC1, but normalized with disease progression and then decreased relative to WT
at 18 weeks of age and in zQ175 hearts at 12 months of age (Figure 54A-B). Levels of the LC3pro and LC3-I followed a pattern opposite LC3-II: both increased in N171-82Q heart lysates
starting at 10 weeks of age for LC3-Pro and 14 weeks of age for LC3-I (Figure 54A, C-D). These
changes suggest attenuated autophagy in late-stage HD hearts despite low levels of mTORC1
activity, which may result from impaired initiation or inhibited degradation of autophagic vesicles
(flux). To distinguish between the two, I measured protein levels of SQSTM1/p62 and Beclin-1.
The only difference I found occurred in 14 week-old N171-82Q mice, at which point p62 levels
were mildly elevated, but the magnitude was low and it is therefore probably not physiologically
relevant (Figure 55A-C). In HD hearts, then, autophagic flux does not appear to be impaired, so
limited autophagic initiation via an mTORC1-independent mechanism is the more likely

85

explanation. However, further investigation must be undertaken to confirm this hypothesis, as well
as to understand its functional relevance.
Another potential mechanism affected by mTORC1 dysregulation is mitochondrial
biogenesis, a process mediated by the transcription factor and mTORC1 target peroxisome
proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α) (116). In HD brains, PGC-1α
expression and many of its downstream target genes were downregulated relative to WT, and
restoration of mTORC1 activity improved those abnormalities (24, 130). With similar mTORC1
dysregulation between the heart and brain in HD mice, and mitochondrial abnormalities
implicated in HD mouse hearts (37, 91), I expected to find decreased cardiac Pgc-1α levels.
Surprisingly, expression of Pgc1α and its co-transcription factor Nrf1 was increased relative to
WT in N171-82Q hearts starting at 14 weeks of age (Figure 56A-B). Nrf1 was also mildly but
significantly upregulated in 12 month-old zQ175 mouse hearts. However, expression of Pgc1α/Nrf1 downstream target genes did not follow the same pattern: Tfam and Idh3a levels in HD
hearts were equal to WT except in N171-82Q mouse hearts at 10 weeks, at which point they
were decreased (Figure 56C-E). Atp5g1 levels were also lower in both 10 week-old and 14
week-old N171-82Q mouse hearts. The resulting relationship between Pgc-1α expression and
one of its downstream target Idh3a (Figure 56F) suggests that cardiomyocytes may be struggling
to maintain expression of functional mitochondrial proteins (Idh3a and Atp5g1), and the rising
levels of Pgc-1α and Nrf1 may be an attempt at compensation. This process appears to occur
independent of mTORC1 activity, but further work is necessary before any conclusions can be
made.
Discussion
In the heart, mTORC1 mediates adaptive hypertrophy, so its dysregulation in HD mouse
hearts may result in decreased compensation and increased sensitivity to stress. In this chapter I
show that symptomatic N171-82Q and zQ175 mice have increased mortality when continuously
infused with isoprenaline for 14 days. On echocardiogram HD mice have increased rate and
contractility throughout the trial but do not experience increased LV mass; conversely, WT mice
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have increased LV mass evident by trial day 5 but have normal rate and contractility. Postmortem analysis showed that ISO-stressed N171-82Q mouse hearts fail to hypertrophy and have
increased fibrosis relative to stressed WT hearts. Importantly, these phenotypes were reversed in
N171-82Q mice injected with CT.AAV.caRheb, showing that restoration of cardiac mTORC1 in
HD animals allows adaptation to stress and prevents pathologic changes. These studies thus
conclude that one of the main HD heart phenotypes is increased sensitivity and impaired
adaptation to stress, and the molecular mechanism underlying it is cardiac mTORC1
dysregulation.
One of the most interesting, unanswered questions in the cardiac stress studies is why
do stressed HD mice die? Arrhythmias related to chronic adrenergic stimulation is one potential
explanation (170), but the amount of fibrosis in stressed HD mouse hearts suggests a less acute,
pathogenic process. Echocardiography showed that HD mouse hearts respond to the chronic
ISO by maintaining a sustained increase in rate and contractility, which is the response expected
with acute adrenergic stimulation, but it is atypical after 5 or 12 days of chronic treatment.
Adaptive hypertrophy is a key mechanism in improving myocardial efficiency and decreasing
energy expenditure: applying Laplace’s law, increasing the ventricular wall thickness decreases
wall tension, and therefore decreases the amount of work required with each contraction (159,
171). Thus, in the absence of adaptive hypertrophy, stressed HD hearts exist in a state of high
energy usage and become susceptible to exhaustion. Indeed, I found qualitatively that most of
the myocardial fibrosis was at the areas furthest from coronary blood supply, occurring in a
pattern similar to ischemic injuries associated with maladaptive heart hypertrophy (82). In
stressed HD mouse hearts, impingement of small coronary vessels by excessive cardiac tissue is
unlikely, but it may be that the tissue’s oxygen usage is so high that even healthy coronary
arteries cannot meet the demands. The exhaustion hypothesis is strengthened by the evidence
pointing to mitochondrial abnormalities in HD hearts (91): in a state of high energy expenditure,
impaired energy production would be detrimental. Ideally, metabolic testing of ex vivo perfused
hearts coupled with sensitive measurements of various energy-associated molecules such as
ATP, ADP, and creatinine in stressed HD hearts could help confirm this hypothesis.
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Many of the analyses are confounded by a survivor bias. Attrition almost always occurred
before humane end points could be assessed, and though histologic characteristics examined
here were typically preserved after a significant post-mortem interval, RNA expression, lung fluid,
and protein phosphorylation were generally degraded. Thus, the wet/dry lung mass ratios
reported here may not have differed because all of the mice that went into decompensated heart
failure died before they could be euthanized and tissues collected (lungs that were collected from
animals that died in situ were found to be too degraded to provide accurate fluid level
assessment). Additionally, for both N171-82Q and zQ175 mice, mortality occurred almost entirely
within the first half of the trial. As a result, the 40-50% of ISO-treated HD mice that survived must
have been able to mount some sort of adaptive response, which could have confounded results.
This subpopulation does raise interesting questions, such as what mechanisms allowed survival
in spite of a baseline mTORC1 dysregulation? Given the severe and rapid mortality in 18 monthold zQ175 mice, it is likely that age-related mechanisms are a major component. Future work
should be directed at clarifying both the end-of-life phenotype for the HD mice that don’t survive
chronic ISO-stress, and understanding how other HD mice do survive.
One of the most exciting findings from these studies is clarification of an HD-related heart
phenotype that can focus epidemiological and other clinical studies. While heart disease is a
common cause of death for HD patients, it is also a common cause of death for the general
population. These studies suggest that HD many not be associated with an increased incidence
of heart disease. However, if an HD patient develops any form of chronic cardiovascular
disease—as a result of lifestyle, genetics, etc.—it may progress to heart failure and death far
more quickly than in unaffected individuals.
Materials and Methods
Animals
As in other chapters, all animal protocols were approved by the Animal Care and Use
Committee at The Children’s Hospital of Philadelphia (CHOP). N171-82Q and heterozygous
zQ175 HD murine model lines were obtained from Jackson Laboratories (Bar Harbor, ME) and
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maintained on a B6C3F1/J (N171-82Q) or C56B6/J (zQ175) background. Mice were genotyped
using primers specific for human HTT, and age-matched WT littermates were used as controls for
all experiments. All experiments were performed with male mice exclusively. Animals were
housed in enriched, temperature-controlled environments with a 12-hour light/dark cycle. Food
and water were provided ad libitum.
Cardiac Stress Induction
Cardiac stress was induced by constant infusion of isoprenaline (ISO, also known as
isoproterenol, Sigma) using osmotic minipumps (Alzet). ISO was administered at a dose of 30
mg/kg/day for 14 days. Pumps were filled using sterile procedures and primed in sterile PBS at
37°C for 24 hours prior to implantation. ISO administration was started at 12 weeks of age for
N171-82Q mice and 18 months of age for zQ175 mice. Implantation procedure followed
manufacturer’s recommended protocol and was performed using sterilized equipment. Briefly,
mice were anesthetized using isoflurane and placed in the prone position. The subscapular
region of the back was shaved and cleaned, and a small, subcutaneous, horizontal incision was
made at midline just caudal to the scapulae. A closed hemostat was inserted caudally about 1
inch, gently opened about 1 cm, and withdrawn, disrupting connective tissue bonds and forming a
small pocket for the pump. While ideally the pump should sit midline, in early experiments it
always drifted to one side; thus, in later trials the pocket was angled towards the mouse’s right
side in order to prevent distorting the optimal window for echocardiography. The pump was
inserted with the flow regulator pointed caudally so as to avoid drug leakage out of the incision.
The incision was close with wound clips, which were removed 7-10 days after surgery.
Transthoracic Echocardiography
Similar to echocardiography in chapter 2, all echo procedures were performed at the
CHOP Small Animal Imaging Facility. Mice were anesthetized with 2.5% isoflurane and
positioned on a heated stage with continuous EKG measurement. Transthoracic
echocardiograms were recorded using an MS-400 30 MHz probe connected to a Vevo 2100 or
3100 imager with cardiovascular measurement package. (Fujifilm VisualSonics). Parasternal long
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axis views with Doppler were used to calculate aortic ejection time and mitral valve flow
dynamics. Parasternal short axis M-mode views at the level of papillary muscles were used to
calculate posterior wall, septum, and ventricular diameter each at end diastole and end systole.
Images were acquired and dimensions measured by Christine J. Pascua, an experienced
operator blinded to mouse genotype. Stroke volume was calculated as the difference between left
ventricular end diastolic and systolic volumes, and cardiac output calculated as the stroke volume
multiplied by the heart rate.
Heart Mass Analysis
Mice were massed, then anesthetized with a mixture of ketamine/xylazine (IP injection of
100 mg/kg and 10 mg/kg, respectively) and transcardially perfused with cold saline. Unlike
previously, hearts were excised and atria removed before being blot-dried and massed on an
analytical balance. Left tibias were removed and measured with electronic calipers to control for
variation in total body size.
Western Blots
For in-depth western blot protocol, see Chapter 3: Materials and Methods. Briefly, protein
was extracted from heart samples using RIPA buffer and total protein concentration was
determined by BCA (Pierce). 30 µg of protein was reduced and separated by SDS-PAGE on 12%
bis-tris polyacrylamide gels in MOPS buffer (Bio-Rad), then transferred to 0.2 µm PVDF (BioRad). Antibodies used are described in Table 4. Blots were developed using ECL Plus Western
Blotting Detection System (GE Healthcare) and imaged digitally on a ChemiDoc MP imaging
system (Bio-Rad). Blots were stripped no more than two times using Restore Stripping Buffer
(Thermo) for 9 minutes at 37°C. Densitometry was performed using NIH ImageJ software.
Densities of bands detected by phospho-antibodies were normalized to densities of bands
detected by phospho-independent antibodies in same lane. Phospho-independent antibody
densities were normalized to αTubulin or Na/K-ATPase band in same lane.
Histology
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As before, excised hearts were bisected transversely at the approximate midpoint, and
apical portions were post-fixed overnight in 4% paraformaldehyde. Heart tissue was dehydrated
and embedded in paraffin by the CHOP Pathology Core, and sectioned to 5-7 µm on a rotary
microtome (Microm HM 355s). Mounted sections were heated at 56-60°C for 20 minutes to
remove excess paraffin, flatten sections, and prevent detachment. Sections were allowed to cool
to RT and rehydrated before continuing with staining procedures. All sections were imaged on a
Leica DM6000B light microscope.
Wheat germ agglutinin: sections were washed twice for two minutes in tap water, then
placed into a solution of 10 µg/ml wheat germ agglutinin and 2 µg/ml Hoechst stain in
PBS. Slides were stained for 15 minutes at 37°C, then washed twice for two minutes in
deionized water and mounted with fluorogel. For quantitative analysis, images were taken
throughout the posterior wall to encompass all transversely-sectioned cells. ImageJ was
used to overlay a grid on each image to randomly select approximately 50 cells/image
and cross-sectional area was measured for each selected cell by either manually
circumscribing the cell exterior or using the threshold function and magic wand tool. At
least 200 cells were measured per heart.
Masson’s Trichrome stain: sections were incubated in 56°C Bouin’s solution (Sigma) for
10 minutes, followed by staining with Masson’s Trichrome (Sigma) according to standard
procedure. Briefly, tissues were stained with working Weigert’s iron hematoxylin for 5
minutes, rinsed in deionized water, and then stained in Biebrich scarlet-acid fuchsin for 5
minutes. Slides were rinsed in deionized water, fixed in working
phosphotungstic/phosphomolybdic acid solution for 5 minutes, and then immediately
stained with aniline blue solution for 5 minutes. Sections were destained in 1% acetic
acid for 2 minutes, rinsed in deionized water, dehydrated through ethanol, cleared in
xylene, and mounted.
Picrosirius Red stain: slides were stained with Weigert hematoxylin (Sigma) for 8
minutes, rinsed for 10 minutes in running tap water, then incubated for 1 hour in a 0.1%
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solution of Direct Red 80 (Sigma) in saturated aqueous picric acid (1.3%). Destaining
was accomplished by incubating slides in two rinses of 0.5% aqueous acetic acid for 1
minute each. Slides were then dehydrated through ethanol, cleared in xylene, and
mounted with DPX. Low-power images were taken using both a standard bright field filter
and a polarizing filter. At least 9 images were collected per heart, intended to capture a
large section of the left ventricle. Large vessels were avoided because of their high
collagen content. ImageJ was used to threshold and measure area of each image, and
percent of total area occupied by fibrotic tissue was calculated by dividing the area of the
polarized image by the area of the standard image.
Quantitative PCR
For in-depth explanation of qPCR protocol, see Chapter 2: Materials and Methods.
Briefly, RNA was extracted from snap-frozen mouse hearts using Trizol (Ambion). cDNA libraries
were constructed from 2 µg RNA template using with random hexamer primers and a High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). SYBR Green qPCR was
performed using either custom-designed primer sets, or pre-designed and validated primer sets
purchased from IDT. Genes that utilized pre-designed primers sets in this chapter include: Nrf1,
Idh3a, and Atp5g1. For custom-designed primer sets used in this chapter, see Table 5. Data was
analyzed using either the 2-ΔΔCt method, or by creating a standard curve from known
concentrations of plasmid DNA each containing a single copy of the gene of interest.
Statistical Analyses
Survival curves were analyzed by Mantel-Cox (Log-Rank) test. Echocardiography data
was analyzed by one-way ANOVA with Sidak’s multiple comparison test. All other data was
analyzed by one-way ANOVA with Tukey’s post-hoc analysis or Student’s T-test. For all statistical
analyses p ≤ 0.05 was considered significant. All statistics were performed in GraphPad Prism
version 7.
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Table 4: Antibodies used for Chapter 4
Company
Cell Signaling

Abgent
AbCam
Thermo Fisher
Sigma
GE Healthcare

Antigen
P-S6 (ser235/236)
S6
P-4EBP1 (ser65)
4EBP1
P-Akt (ser473)
Akt
P-mTOR (ser2448)
mTOR
Rheb
LC3
Beclin 1
SQSTM/p62
GFP
αTubulin
Anti-mouse HRP
Anti-rabbit HRP

Product ID
4858
2217
9451
9644
4060
4691
5536
2983
13879
APG8B
ab207612
ab56416
A11122
T5168
NA931
NA934
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WB Dilution
1:1000
1:1000
1:500
1:1000
1:500
1:1000
1:500
1:1000
1:1000
1:500
1:2000
1:1000
1:1000
1:2000
1:20,000
1:15,000

Table 5: Custom Primers for Chapter 4
Gene Name

Forward Primer

Reverse Primer

Bax

GCAGCTGACATGTTTGCTGATG

AGCCCATGATGGTTCTGATCAG

Bcl2

AGCCTGAGAGCAACCCAATG

CGGTAGCGACGAGAGAAGTC

Pcg1α

CTATGCAGACCTAGATACCAACTC

GCTTCTCTGAGCTTCCTTCAG

Tfam

AGAAAGCACTGGTAAAGAGAAGAG

TGAGCCGAATCATCCTTTGC

Tbp

TACCGTGAATCTTGGCTGTAAAC

GTTGTCCGTGGCTCTCTTATTC
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Figure 36: N171-82Q mice have increased mortality to ISO stress.
Survival curves of N171-82Q and age-matched WT littermates treated with continuous
ISO or saline infusion for 14 days starting at 12 weeks of age. For each group n ≥ 8. N171-82Q
mice experience approximately 50% mortality during the trial period, compared to 15% mortality
in saline-treated HD animals and 0% in either WT treatment group. Mantel-Cox (Log-Rank) test,
**p ≤ 0.01.
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Figure 37: ISO stress causes increased mortality in zQ175 mice.
Survival curve of 18 month-old heterozygous zQ175 mice and age-matched WT
littermates treated with continuous ISO or saline infusion for 14 days. n ≥ 7 for all groups.
Stressed zQ175 mice experienced approximately 83% mortality over the course of the study,
whereas stressed WT mice experienced 25% mortality. Increased mortality in mice of both
genotypes demonstrates the effect of age on ability to respond to stress. Mantel-Cox (Log-Rank)
test, **p ≤ 0.01.
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Figure 38: HD hearts have increased rate and contractility with chronic ISO stress.
Echocardiographic measurements in N171-82Q mice and WT littermates infused with
continuous ISO or saline for 14 days starting at 12 weeks of age. Graphs are depicted as change
from day 0 baseline echoes and represent: (A) left ventricular mass (LV mass), (B) fractional
shortening (FS), (C) heart rate (HR), (D) left ventricular end diastolic volume (LVEDV), (E) left
ventricular end systolic volume, (F) cardiac output (CO), and (G) ejection fraction (EF). n ≥ 5 for
all groups. ISO-stressed WT hearts gain LV mass but have normal FS and HR; ISO-stressed HD
hearts have normal LV heart mass but have increased FS, HR, CO, and EF, indicating increased
contractility and rate. Error bars represent SEM. One-way ANOVA with Sidak’s multiple
comparison analysis, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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Figure 39: ISO-stressed HD hearts have blunted gross mass increase.
Comparison of heart mass-to-tibia length ratio in N171-82Q and WT littermates at 12
weeks of age treated with either continuous ISO or saline infusion for 14 days. Stressed WT
hearts experience 35% mass increase relative to saline-treated WT hearts. Stressed HD hearts
experience only 17% mass increase relative to unstressed HD hearts, suggesting a blunted
response. Note that only mice that survived to trial endpoint were included in the analysis. n ≥ 7
for each group. Error bars represent SEM. One-way ANOVA with Tukey’s post-hoc analysis, *p ≤
0.05, ***p ≤ 0.001.
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Figure 40: HD mouse cardiomyocytes do not hypertrophy in response to ISO stress.
Wheat germ agglutinin staining and measurement of cross-sectional area in heart
sections taken from N171-82Q and WT littermates treated with either ISO or saline for 14 days
starting at 12 weeks of age. ISO-stressed WT mice had a significant increase in cardiomyocyte
cross-sectional area relative to saline treated WT mice, whereas cardiomyocyte cross-sectional
area was not different between stressed and unstressed HD mice. N ≥ 7 hearts for each group, n
≥ 200 cells measured per heart. Scale bars = 20 µm. Error bars represent SEM. One-way
ANOVA with Tukey’s post-hoc analysis, **p ≤ 0.01.
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Figure 41: Stressed HD hearts are more fibrotic than stressed WT hearts.
Representative staining and quantitation of fibrosis in heart sections from N171-82Q mice
and WT littermates treated with continuous ISO or saline for 14 days starting at 12 weeks of age.
(A-B) Picrosirius red stain: fibrotic tissue (A) stains bright red using standard bright field
techniques, and (B) is birefringent when viewed through a polarizing filter. (C) Masson’s trichrome
stain: cellular proteins stain red, nuclei stain black, and fibrotic tissue stains bright blue. (D)
Quantitation of fibrosis expressed as percent area occupied by fibrotic tissue using picrosirius red
images. N ≥ 12 hearts for each group, n ≥ 9 images per heart. Scale bars = 100 µm. Error bars
represent SEM. One-way ANOVA with Tukey’s post-hoc analysis, ***p ≤ 0.001.
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Figure 42: ISO-stressed mouse hearts have pro-apoptotic gene expression changes.
Quantitative PCR analysis of genes associated with apoptosis in hearts from N171-82Q
and WT mice treated with ISO or saline for 14 days starting at 12 weeks of age. (A) Expression of
the pro-apoptotic gene Bax, and (B) expression of the anti-apoptotic gene Bcl2. Stressed hearts
from both WT and HD mice have increased Bax expression and decreased Bcl2 expression
relative to unstressed hearts of the same genotype, suggesting that stress promotes apoptosis
regardless of genotype. However, expression changes, while statistically significant, are relatively
mild. Tbp was used as an internal control and data are graphed relative to expression in hearts
from saline-treated WT mice. Error bars represent SEM. One-way ANOVA with Tukey’s post-hoc
analysis, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.

101

Figure 43: Decompensated heart failure is not occurring in ISO-treated mice.
Wet/dry lung mass ratio in ISO- or saline-treated N171-82Q or WT mice at after 14 days
of treatment starting at 12 weeks of age. Increased wet/dry lung ratio results from fluid backup
due to inefficient LV function and is indicative of decompensated heart failure. There were no
differences between any of the treatment groups, suggesting that at this time point heart failure is
not occurring. Note that the data here do not include mice that died before trial endpoint. n ≥ 7 for
all groups. Error bars represent SEM. One-way ANOVA with Tukey’s post-hoc analysis.
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Figure 44: mTORC1 activity is increased in hearts from stressed HD mice.
(A) Representative western blot lanes and quantitation of (A) P-S6 levels and (B) P4EBP1 levels in hearts from N171-82Q and WT mice treated with ISO or saline for 14 days
starting at 12 weeks of age. n ≥ 7 for each group. P-S6 levels were increased in ISO-stressed HD
mouse hearts relative to unstressed HD and WT hearts. Note that these data include only mice
that survive to trial endpoint, so an endogenous ability to overcome decreased mTORC1 activity
in response to stress may be associated with better survival outcomes. Error bars represent
SEM. One-way ANOVA with Tukey’s post-hoc analysis, *p ≤ 0.05.
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Figure 45: Confirmation of caRheb and GFP transduction in HD mouse hearts.
Western blot confirmation of caRheb (R) or GFP (G) expression in hearts from N171-82Q
mice injected with either CT.AAV.GFP or CT.AAV.caRheb. caRheb is FLAG-tagged, resulting in
increased molecular mass relative to endogenous Rheb.
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Figure 46: Cardiac caRheb expression prevents ISO-related mortality in HD mice.
Survival curves of N171-82Q mice injected with CT.AAV.GFP or CT.AAV.caRheb, then
treated with continuous infusion of ISO or saline for 14 days starting at 12 weeks of age. ISOstressed mice expressing GFP treated experienced 40% mortality by study end point compared
to only 5% in stressed mice expressing caRheb. Thus, restoring mTORC1 activity in HD mouse
hearts rescues stress-associated mortality. n ≥ 12 for all groups. Mantel-Cox (Log-Rank) test, **p
≤ 0.01.
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Figure 47: Cardiac caRheb expression restores normal stress adaptation in HD hearts on
echocardiography.
Transthoracic echocardiography measurements in N171-82Q mice injected with
CT.AAV.caRheb or CT.AAV.GFP and treated with ISO or saline for 14 days starting at 12 weeks
of age. n ≥ 4 for each group. Data are graphed as changes from day 0 (baseline) measurements
and include: (A) LV mass, (B) FS, (C) HR, (D) LVEDV, (E) LVESV, (F) CO, and (G) EF. Similar to
before, HD mice expressing GFP experience do not have increased LV mass but experience
increased FS, HR, and EF in response to ISO treatment. Conversely, HD mice expressing
caRheb experience increased LV mass in response to ISO treatment, but have normal FS and
HR, thus replicating the WT phenotype. Error bars represent SEM. One-way ANOVA with Sidak’s
multiple comparison analysis, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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Figure 48: caRheb expression in HD mouse hearts permits hypertrophy in response to
stress.
Heart mass-to-tibia length ratio in N171-82Q mice injected with CT.AAV.caRheb or
CT.AAV.GFP and treated with ISO or saline for 14 days starting at 12 weeks of age. In caRhebexpressing mice treated with saline, heart mass-to-tibia length ratio increased by 27% relative to
GFP-expressing mice treated with saline. Thus, gross size analysis shows restoration of the
hypertrophic response following mTORC1 activity activation. One-way ANOVA with Tukey’s posthoc analysis, ***p ≤ 0.001.
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Figure 49: Cardiac caRheb expression in HD mice restores ISO-induced cardiomyocyte
hypertrophy.
Wheat germ agglutinin staining and measurement of cardiomyocyte cross-sectional area
in heart sections from N171-82Q mice injected with CT.AAV.caRheb or CT.AAV.GFP and treated
with ISO or saline for 14 days starting at 12 weeks of age. Cardiomyocyte cross-sectional area
was equal between saline- and ISO-treated GFP-expressing mice. There was a slight but
significant increase in cardiomyocyte cross-sectional area in saline-treated caRheb-expressing
mice relative to saline-treated GFP-expressing mice, and there was a robust increase in
cardiomyocyte cross-sectional area of ISO-treated caRheb-expressing mice compared to all other
treatment groups. Thus, restoration of mTORC1 activity in HD mouse hearts restores the ability to
hypertrophy in response to ISO stress. N ≥ 7 hearts for each group, n ≥ 200 cells measured per
heart. Scale bars = 20 µm. Error bars represent SEM. One-way ANOVA with Tukey’s post-hoc
analysis, **p ≤ 0.01, ***p ≤ 0.001.
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Figure 50: Cardiac caRheb expression prevents ISO-induced fibrosis in HD mouse hearts.
Representative staining and quantitation of fibrosis in heart sections from N171-82Q mice
injected with CT.AAV.caRheb or CT.AAV.GFP treated with continuous ISO or saline for 14 days
starting at 12 weeks of age. (A-B) Picrosirius red stain: fibrotic tissue (A) stains bright red using
standard bright field techniques, and (B) is birefringent when viewed through a polarizing filter.
(C) Masson’s trichrome stain: cellular proteins stain red, nuclei stain black, and fibrotic tissue
stains bright blue. (D) Quantitation of fibrosis expressed as percent area occupied by fibrotic
tissue using picrosirius red images. N ≥ 8 hearts for each group, n ≥ 9 images per heart. Scale
bars = 100 µm. Error bars represent SEM. One-way ANOVA with Tukey’s post-hoc analysis, ***p
≤ 0.001.
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Figure 51: ISO stress induces mild pro-apoptotic gene expression in HD hearts expressing
caRheb.
Quantitative PCR analysis of genes associated with apoptosis in hearts from N171-82Q
injected with CT.AAV.caRheb or CT.AAV.GFP and treated with ISO or saline for 14 days starting
at 12 weeks of age. (A) Expression of the pro-apoptotic gene Bax, and (B) expression of the antiapoptotic gene Bcl2. Bax expression was increased only in hearts from ISO-treated caRhebexpressing mice, and Bcl2 was not different among any of the treatment groups. Note that only
mice that survived to trial endpoint are included in this analysis. Tbp was used as an internal
control and data are graphed relative to expression in hearts from saline-treated CT.AAV.GFPinjected mice. n ≥ 5 for each group. Error bars represent SEM. One-way ANOVA with Tukey’s
post-hoc analysis, **p ≤ 0.01, ***p ≤ 0.001.
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Figure 52: Heart failure is not occurring in ISO-stressed HD mice injected with either
CT.AAV.GFP or CT.AAV.caRheb.
Wet/dry lung mass ratio in ISO- or saline-treated N171-82Q mice after 14 days of
treatment starting at 12 weeks of age following injection with CT.AAV.caRheb or CT.AAV.GFP.
There were no differences between any of the treatment groups, suggesting that at this time point
heart failure is not occurring. Note that the data here do not include mice that died before trial
endpoint. n ≥ 5 for all groups. Error bars represent SEM. One-way ANOVA with Tukey’s post-hoc
analysis.
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Figure 53: ISO stress promotes mTORC1 activity in HD mice injected with either
CT.AAV.caRheb or CT.AAV.GFP.
(A) Representative western blot and quantitation of (B) P-S6 and (C) P-4EBP1 levels in
hearts from N171-82Q mice injected with CT.AAV.caRheb or CT.AAV.GFP and treated with ISO
or saline for 14 days starting at 12 weeks of age. P-S6 levels are increased in hearts from ISOstressed mice injected with either vector. P-4EBP1 levels are increased only in hearts from
stressed HD mice expressing caRheb. Only mice that survived to trial endpoint, so data imply that
overcoming the decreased mTORC1 activity with stress in HD mice may be associated with
survival. Error bars represent SEM. One-way ANOVA with Tukey’s post-hoc analysis, *p ≤ 0.05,
**p ≤ 0.01, ***p ≤ 0.001.
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Figure 54: LC3 processing decreases with disease progression in HD mouse hearts.
(A) Representative western blot and quantitation of (B) LC3-II, (C) LC3-Pro, and (D) LC3I levels in hearts from N171-82Q and WT mice at 6 (n ≥ 6), 10 (n ≥ 7), 14 (n ≥ 8), and 18 (n ≥ 8)
weeks of age, and in zQ175 mice and WT littermates at 12 months of age (n ≥ 10). At 6 weeks,
N171-82Q mice have increased LC3-II and normal LC3 precursors, consistent with increased
autophagy. As disease progresses, however, LC3-II levels first normalize then decrease relative
to WT, concomitant with an increase in LC3-Pro starting at 10 weeks of age and an increase in
LC3-I starting at 14 weeks of age. In 12 month-old zQ175 mice, both LC3-II an LC3-I are
decreased relative to WT. Together these data suggest that in young HD mice autophagy is
increased, consistent with decreased mTORC1 activity. However, as mice get older and disease
progresses, autophagy gradually slows down and is inhibited by an mTORC1-independent
pathway. Band densities were normalized to density of αTubulin band in the same lane. Data are
graphed relative to WT for each time point and error bars represent SEM. Student’s T-test, *p ≤
0.05, **p ≤ 0.01, ***p ≤ 0.001.
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Figure 55: Autophagy-associated protein levels are not affected in HD mouse hearts.
(A) Representative western blot with densitometry quantitation of (B) p62 levels and (C)
Beclin1 levels in N171-82Q and WT mouse hearts at 6 (n ≥ 6), 10 (n ≥ 7), 14 (n ≥ 8), and 18 (n ≥
8) weeks of age, and in zQ175 and WT mouse hearts at 12 months of age (n ≥ 10). P62 levels
are mildly increased in 14 week-old N171-82Q mouse hearts, but the magnitude is unlikely to be
physiologically relevant. Otherwise, no differences are observed between HD and WT at any time
point. Thus, autophagic flux may not be affected in HD mouse hearts. Error bars represent SEM.
Student’s T-test, **p ≤ 0.01.
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Figure 56: PGC1α signaling is altered in HD mouse hearts
Quantitative PCR analysis of genes regulated by mTORC1 and associated with
mitochondrial biogenesis in N171-82Q and WT mice at 6 (n ≥ 6), 10 (n ≥ 7), 14 (n ≥ 8), and 18 (n
≥ 8) weeks of age, and in zQ175 mice at 12 months of age (n ≥ 10): (A) Pgc1α, (B) Nrf1, (C)
Tfam, (D) Idh3a, (E) Atp5g1. (F) is a comparison of Pgc1α expression with that of Idh3a, one of
its downstream target genes. Pgc1α and its co-transcription factor Nrf1 are both upregulated in
N171-82Q mice starting at 14 weeks; Nrf1 is also upregulated in 12 month-old zQ175 mice.
However, expression of their immediate target Tfam and further downstream genes are only
different from WT at 10 weeks in N171-82Q mice, at which point they are downregulated to WT.
Tbp was used as an internal control. Data is graphed relative to WT for each time point and error
bars represent SEM. Student’s T-test, *p ≤ 0.05, **p ≤ 0.01.
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CHAPTER 5: DISCUSSION AND FUTURE DIRECTIONS
The vast majority of Huntington’s disease research justifiably focuses on its neurologic
phenotypes: profound neurodegeneration, particularly within the striatum, is a hallmark of the
disease that explains its most characteristic and severe signs and symptoms (1). Multiple
therapeutic strategies have been attempted since the discovery of the HTT gene, but, as with
most other genetic diseases, a cure has so far remained elusive. Fortunately, recent progress in
gene therapy approaches have led to the promise of a cure for HD (33, 35), though the nature of
the therapy requires limiting distribution to the CNS. Thus, the peripheral effects of mHTT
expression will still need to be addressed. HD patients experience a myriad of phenotypes
outside the CNS, including increased peripheral inflammation, cardiac abnormalities, weight loss,
skeletal muscle dysfunction, and metabolic abnormalities (172). Understanding and treating these
signs and symptoms can lead to profound quality of life improvements for HD patients, and some
of them have even been shown to have a direct effect on disease progression (173).
Furthermore, HTT-targeting gene therapies within the CNS will unmask these peripheral
phenotypes and present new clinical challenges.
An association between heart disease and HD has existed since before the discovery of
the HTT gene (40, 42), but the phenotype has not been well studied. Many of the clinical studies
that examine the heart in HD are limited by small patient numbers and noninvasive edge-of-bed
analyses (47-51). Multiple factors contribute to this gap, including, significantly, the large number
of participants needed to account for confounding factors associated with heart disease in large,
observational studies (43)—a major challenge when studying a rare disease like HD. Other
limitations to understanding the heart in HD are self-imposed, such as exclusion of patients with
history of heart disease from HD-specific studies, failure to record cardiovascular measurements
in large, observational studies and databases, and the difficulty/expense of obtaining postmortem tissue samples.
As a result of the limitations surrounding heart research in HD patients, most
understanding of the HD heart phenotype is inferred from mouse models. However, only a
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handful of such studies have been published to date, many of them simply descriptive studies
highlighting the characteristics unique to different HD mouse models (37, 83, 85, 86). Very few
studies aimed to determine the mechanisms underlying the noted cardiac phenotypes common
across HD mouse lines (91). Thus, the work I present in this thesis is significant because I
propose that cardiac mTORC1 dysregulation in HD impairs adaptive hypertrophy and thus
increases mortality with cardiac stress. While these studies were performed in mice, they provide
shape and focus to future epidemiological and clinical studies and raise questions that can be
answered with the patient-centered tools available.
The statistics from death certificates citing heart disease as the second leading cause of
death should be interpreted cautiously for several reasons (40-42). First, the accuracy of the
death certificate depends on the acumen of the person filling it out. Second, “heart disease” is an
extremely broad characteristic and, while it narrows the field, it does little else to suggest a
phenotype. Third, heart disease is common in the general population, so these statistics suggest
an association between HD and the heart where none may actually exist. In fact, the authors of
the original death certificate analysis reported that, despite accounting for a significant proportion
of deaths, heart disease was not reported more frequently in patients dying with HD; they
therefore postulated that incidence of heart disease is similar between HD and unaffected
populations (40). The findings I present in this thesis support that conclusion. Contrary to reports
of inherent pathological processes in other mouse models (37, 83-86), I found no evidence of
pathology in hearts from N171-82Q and zQ175 mice relative to WT in the absence of stress. My
work thus centers on understanding the markedly smaller hearts in HD mouse models, a finding
consistent with the only published study to date that examined the post-mortem heart in HD
patients (46) and replicated by many HD mouse models (37, 84, 86).
My studies showed that mTORC1, a master regulator of growth and metabolism, is
dysregulated in HD mouse hearts starting at an early time point and continuing throughout
disease. Consequently, I found that this diminished mTORC1 activity restricts adaptive cardiac
hypertrophy in HD mice, underlying the pathologic processes that ensue in response to stress.
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These observations, then, may subtly change the interpretation of the death certificate statistics:
the important conclusion may not be that HD is associated with heart disease, but rather that HD
is associated with death from heart disease. Future epidemiologic studies focusing on the heart in
HD should explore this distinction and seek to establish the incidence and prevalence of heart
disease among the HD patient population. More specifically, research should investigate the
length of time between onset of heart disease and death in HD patients compared to unaffected
relatives. Additionally, clinical studies should be designed to recruit HD patients diagnosed with
heart abnormalities and follow them longitudinally to gain a clearer understanding of how heart
disease progresses in HD patients vs. an unaffected, age-, sex-, and BMI-matched individual.
In the experiments I report here, cardiac stress is associated with poor survival in HD
mouse models. Conversely, regular exercise not only improves numerous psychosocial metrics
for HD patients, it is also one of the few interventions to consistently show therapeutic
effectiveness for improving motor function, gait, and balance (174). Both the cardiac stress model
I induced and exercise-related stress are mediated by adrenergic signaling (157), but the crucial
difference between the two is timing. Chronic adrenergic stimulation typically only occurs in
response to an underlying pathology such as systemic hypertension or valvular stenosis, whereas
exercise-related stress is acute, sporadic, and rarely causes maladaptive changes (157).
Additionally, regular exercise is associated with decreased frequency of cardiovascular diseases
characterized by chronic stress, such as coronary artery disease or hypertension (175). Thus, HD
patients who exercise regularly would be expected to not only experience the neurologic and
psychosocial benefits, but also be protected from potentially serious cardiovascular conditions.
As discussed throughout this thesis, the cell-autonomous effect of mHTT expression in
peripheral tissues is difficult to separate from abnormal neuronal inputs. Though certain
peripheral systems such as the liver and immune system are capable of exerting some influence
over brain physiology (172), nervous tissue is classically isolated from systemic conditions. Thus,
the cell-autonomous effects of mHTT in the CNS are well-established. However, nearly every
other tissue in the body receives some form of input from the brain, and thus identifying where a
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particular peripheral phenotype originates is more difficult. The work I present in Chapter 3
attempts to conclusively determine the necessity and sufficiency of mHTT expression for cardiac
mTORC1 dysregulation. I was able to show that mHTT is necessary for the phenotype, but due to
relatively low levels of overexpression I was not able to conclude if it was sufficient or not. With
these data it is thus impossible to know how much of the phenotype relies on altered neuronal
inputs. Multiple approaches could be taken to address the technical concerns with the
experiment—including using a stronger promoter, incorporating enhancer elements, or changing
the virus serotype—but even with the best transduction system, efficiency will be less than 100%
and therefore not a perfect replica of a transgenic animal. It would thus be of great benefit to the
community that engage in research on peripheral HD phenotypes to engineer a set of mice that
allows conditional tissue-specific expression or knockout of a mHTT transgene or allele. These
models could help to conclusively determine which phenotypes result from neurodegeneration
and which result from cell autonomous effects in any number of peripheral tissues, and would
thus help to direct potential therapeutics seeking to correct these abnormalities.
Restoration of cardiac mTORC1 by caRheb transduction in N171-82Q mice restored
adaptive hypertrophy in response to stress and mimicked the WT response. Consequently, mice
expressing cardiac caRheb experienced only limited fibrosis and mortality. However, using
caRheb to activate mTORC1 is employed here only as an experimental proof-of-concept
technique and should not be considered a potential therapy for treating an HD heart phenotype.
Constitutively activating mTORC1, as might occur through a genetic approach, was obviously
beneficial to HD mice in the short term, but it has a myriad of potential long-term complications
including cardiac rhabdomyoma, arrhythmia, and heart failure (176). The most ideal therapeutic
strategy in HD is, of course, to treat the root cause by decreasing levels of mHTT, regardless of
tissue type (2). But because tissue-specific gene delivery is challenging, and the HD heart
phenotype seems to be relatively benign except under stress circumstances, a small molecule
approach may be a very viable option.
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Small molecule inhibitors of mTORC1 are abundant, specific, and used often in clinical
settings as immunosuppressive and antineoplastic agents. On the other hand, mTORC1-specific
activators are considerably less-common, and none are clinically-approved. (Considering the
narrow set of clinical scenarios in which increased mTORC1 activity might be beneficial, this lack
of resources is understandable.) Hence, this work provides justification for drug discovery and
preclinical testing of new molecules that promote mTORC1 signaling. Another intriguing
possibility is either oral leucine or BCAA supplementation, a treatment regimen that has been
shown to augment mTORC1 activity in skeletal muscle biopsies from healthy volunteers (177).
However, the utility of this therapy for HD patients depends on the mechanism of mTORC1
dysregulation. Intraperitoneal injections of BCAA cocktail over a six week period did not
significantly increase P-S6 or P-4EBP1 levels in HD mice. While further follow-up is needed to
confirm these results, Rheb mislocalization may explain the lack of a robust effect. Intracellular
nutrient sensors respond to ample BCAA levels by recruiting inactive mTORC1 to
endomembranes, where it would normally come into contact with Rheb and become activated
(109). However, if Rheb is mislocalized, as was observed in later-stage N171-82Q mouse hearts,
BCAA supplementation would have little effect (148). A third possible therapeutic strategy is to
identify and target the pathways regulated by mTORC1 that contribute most to the adaptive
hypertrophic stress response. This approach has the benefit of increased specificity and reduced
adverse effects, a particularly attractive quality considering the large number of mTORC1 targets.
In conditional cardiac mTor knockout mice, deletion of 4ebp1 rescued most of the mortality and
pathologic heart phenotype, suggesting that global protein synthesis is the key mTORC1 effector
in adaptive hypertrophy (121). Thus, developing and testing a 4EBP1 inhibitor is an interesting
possibility to attempt to restore proper stress compensation in HD hearts. However, if a large
number of pathways are required for proper stress compensation, transiently increasing activity of
mTORC1 may be the better option.
Collectively, this work establishes a novel link between HD, mTORC1, and adaptive
cardiac hypertrophy. The model that I propose herein is that cardiac mHTT expression
dysregulates mTORC1 activity in HD hearts, either through impaired PI3K/Akt/mTOR axis
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activation or through Rheb mislocalization depending on the disease stage, and this consequently
impairs adaptive heart hypertrophy leading to increased mortality and pathology in response to
stress. Ideally, future work will continue to characterize the cardiac phenotype in HD patients,
establish the role of mHTT expression in cardiomyocytes and how it leads to dysregulated
mTORC1, and develop therapeutic strategies to prevent mortality from heart disease HD patients.
These advances, together with increased understanding of other peripheral HD phenotypes, will
ensure that HD symptoms are well-managed once CNS-directed therapies are approved.
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